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THE CURATIVE POTENTIAL OF CHIMERIC ANTIGEN RECEPTOR T-CELL 
THERAPY FOR B-CELL MALIGNANCIES 
MEGHA PALLAVI KODURI 
ABSTRACT 
Few cancers arising in fluid organ systems can be cured with localized therapeutic 
modalities, such as radiation or surgical organ removal. Chemotherapy and hematopoietic 
stem cell transplants have long been employed as the standard of care for patients 
diagnosed with leukemias and lymphomas. Though research continues to propose new, 
more potent chemotherapeutic agents, a new paradigm of treating cancerous 
malignancies with tumor-specific monoclonal antibodies, adoptively transferred tumor-
fighting cells, and other exogenously administered immunomodulatory agents, has 
emerged over the past decade. These immunotherapies have dramatically improved the 
outcomes of patients diagnosed with cancers of B lymphocytes, referred to as B-cell 
malignancies. 
Though curative FDA-approved therapies for patients diagnosed with B-cell 
malignancies have yet to be established, recent research in the field of adoptive T-cell 
therapy has produced promising results. Tumor infiltrating lymphocyte therapy (TIL 
therapy), T-cell Receptor Therapy (TCR therapy) and Chimeric Antigen Receptor T-cell 
Therapy (CAR T-cell therapy) are the three most extensively studied adoptive T-cell 
immunotherapies in the context of B-cell malignancies. TIL and TCR therapies, in which 
patients are provided with either the patient’s own tumor-specific T-cells or T-cells 
expressing engineered, tumor-specific TCRs, respectively, enhance the patient’s immune 
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system to mount a more potent, anti-tumor response. However, these adoptive T-cell 
therapies do not change the mechanisms of the immune response.  
Cancerous cells can evade immune attack and dampen immune responses to 
survive and thrive in the body. By down-regulating their expression of human major 
histocompatibility complex I (MHC I), for example, cancer cells escape T-cell 
recognition, which is dependent on MHC expression. A chimeric antigen receptor (CAR), 
is composed of an antibody-derived (B-cell derived) extracellular, antigen-recognition 
domain, and T-cell derived intracellular domains. CAR T-cells, therefore, exploit the 
cytotoxic nature of CD8+ T-cells, and the MHC independent recognition of B-cell 
receptors, to identify and destroy all cells expressing a specific target. Consequently, 
many of the cancer cell’s mechanisms of immune evasion are less effective in the 
presence of CAR T-cells. Progressive generations of CAR T-cell designs couple these 
receptors with costimulatory molecules to amplify the activation, efficacy, and potency of 
these cells in-vivo.  
Over the past five years, phase I and IIa clinical trials have produced remarkable 
results in the treatment of advanced stage, high-risk B-cell malignancies, namely Acute 
Lymphoblastic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), and Non-
Hodgkin’s Lymphoma (NHL). However, the significant oncogenic risks and fatal adverse 
events associated with this therapy necessitate further research to improve safety and 
reliable clinical efficacy of CAR T-cell therapy. In spite of these risks, the adoptive 
transfer of CD19-targeting, CAR expressing, cytotoxic T-cells (anti-CD19 CAR-T-cells) 
has produced sustained, complete remissions in patients diagnosed with progressive, 
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advanced-stage, B-cell malignancies, for whom alternative treatments were not available. 
The unprecedented results of early clinical trials, as well as ongoing preclinical studies 
aimed at improving the design and production of CAR T-cells suggest a promising future 
for CAR T-cell therapy as a cure for B-cell malignancies. 
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BACKGROUND 
 
 
Lymphocyte malignancies refer to a set of diseases characterized by the 
uncontrolled division of abnormal lymphocytes. Cancers that affect lymphocytes fall into 
two main categories, leukemias and lymphomas. In leukemias, the original cancerous 
cells are located in the blood or bone marrow, while in lymphomas, the original 
cancerous cells are located in lymph nodes or other related tissues. In both cases, the 
cancer can proliferate outside the compartments of origin to affect multiple tissues and 
body systems (Ansell & Armitage, 2005; Shafer, 1966). Neoplastic cells in leukemias 
and lymphomas may be of B-cell or T-cell origin, and are referred to as B-cell or T-cell 
malignancies, respectively.  
While the human body is typically capable of mounting an immune attack against 
threats to an individual’s health, cancer cells can evade the immune system’s defenses 
and replicative control mechanisms. Research continues to uncover the processes by 
which cancerous cells survive and thrive in the body, yet many cancers remain incurable. 
Though the development of many therapeutic agents has successfully prolonged the life 
of patients diagnosed with high-risk B-cell malignancies over the past decade, 
advancements in immunotherapy hold some of the greatest promise as future cures for B-
cell cancers.  
 
The Immune System 
The immune system, which confers the body’s ability to resist harm, can be 
broken down into two overarching groups: innate immunity and adaptive immunity. 
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Innate immunity is genetically predetermined for each individual, while adaptive 
immunity is learned over an individual’s lifetime. As such, the mechanisms and 
magnitude of the innate immune response do not differ upon repeated exposure to the 
same pathogen. In contrast, the mechanisms of adaptive immunity permanently change 
with exposure to an antigen. Lymphocytes, cells that interact with antigens through 
antigen-specific receptors, confer the specificity of the adaptive immune system  (Mak & 
Saunders, 2006a). 
Lymphocytes, a subset of white blood cells that may reside in the general 
circulation or in lymphoid organs, consist of B lymphocytes (B-cells) and T lymphocytes 
(T-cells). B-cells are derived from bone marrow and can be activated by the presence of 
an antigen to differentiate into antibody producing plasma cells. T lymphocytes mature in 
the thymus, and comprise 60-70% of the total peripheral lymphocyte population 
(Germain, 2002; Pieper, Grimbacher, & Eibel, 2013).  
The three commonly discussed subsets of lymphocytes are naïve lymphocytes, 
effector lymphocytes, and memory lymphocytes. Naïve lymphocytes are mature 
lymphocytes capable of differentiation, but have not yet been exposed to an antigen. 
Effector lymphocytes are short lived cells capable of immediately eliminating antigens. 
Memory lymphocytes are long-lived antigen specific cells that remain dormant until a 
secondary exposure of a pathogen (Chaplin, 2010).  
Two main subsets with distinct functions exist within the memory lymphocyte 
populations: protective memory lymphocytes and reactive memory lymphocytes. Effector 
memory T cells (TEM cells) confer protective memory by migrating to the site of 
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antigenic stimulation and immediately mounting an effector response. Antigen exposure 
stimulates central memory T-cells (TCM cells), which confer reactive memory, to 
proliferate and differentiate into effector T-cells. TCM cells have little effector function 
(Lanzavecchia & Sallusto, 2000).  Within the B-cell populations, plasma cells secrete 
antibodies against pathogens, serving the protective memory function, while memory B-
cells confer reactive memory by proliferating and differentiating into plasma cells upon a 
repeated exposure to the antigen (Ochsenbein et al., 2000). 
When a pathogen enters the body, a single clonal population of lymphocytes is 
capable of recognizing it. Upon recognition, only this clonal population of lymphocytes 
will be stimulated to proliferate and respond to the invader in a process known as clonal 
selection. Upon proliferation, some clones will differentiate into effector lymphocytes to 
respond to the immediate attack, while other clones will differentiate into memory 
lymphocytes. These memory lymphocytes do not participate in the initial attack against 
the pathogen, but remain in a resting state until triggered by a future exposure to the same 
pathogen. These memory lymphocytes are poised to mount a swift and vigorous response 
upon a second exposure to the pathogen (Chaplin, 2010).  
 
T-Lymphocytes 
The two most commonly discussed subsets of T-cells, determined by the cluster 
of differentiation (CD) expressed on the cell surface, are CD4+ helper T-cells (TH cells), 
and CD8+ cytotoxic cells (TC cells). Cell surface molecules CD4 and CD8 function as 
coreceptors for CD4+ helper T-cells, and CD8+ cytotoxic T-cells, respectively, by 
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determining the cell’s compatibility with cell surface proteins known as major 
histocompatibility complexes (MHCs) (Pearce, Shedlock, & Shen, 2004).  Together, an 
antigen and major histocompatibility complex (MHC) form a pMHC unit, which can be 
recognized by T-cell receptors (TCRs). TH cells release cytokines to activate phagocytic 
cells, such as macrophages, to destroy these ingested invaders, or activate B-lymphocytes 
to produce antibodies against these invaders following their recognition of a major 
histocompatibility II (MHC II) domain. TC cells interact with the major 
histocompatibility I (MHC I) domain, which is expressed on most cells in the body, and 
are capable of directly destroying compromised cells (MacLeod, Clambey, Kappler, & 
Marrack, 2009; Swami, 2013). Consequently, T-cells are only capable of recognizing 
antigens as antigen proteins that are bound to MHCs, while B-cells do not require MHCs 
to identify an antigen (Mantegazza, Magalhaes, Amigorena, & Marks, 2013).  
TCRs (figure 1) are essential to T-cell antigen recognition and activation. A 
mature, naïve, or memory T-cell that has not yet encountered its appropriate pMHC unit 
is considered activated when it has been stimulated, by the presence of a recognizable 
antigen, to proliferate and differentiate into an effector T-cell. 
T-cell activation typically requires 2 signals. The first signal is a recognition 
signal, indicating that the T-cell receptor (TCR) has found its cognate antigenic peptide. 
The second signal, originating from the interactions between cosignaling molecules on 
both the antigen presenting cell (APC) and the T-cell, determines whether the T-cell will 
be activated in response to having found its cognate antigenic peptide.  
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Once a TCR interacts with its cognate antigenic peptide in a pMHC unit, CD3 
chains associated with the TCR undergo a conformational change, which initiates an 
intracellular signaling cascade that alters the cytoskeletal structure of the cell (Alarcón, 
Gil, Delgado, & Schamel, 2003; Gomez & Billadeau, 2008; Kane, Lin, & Weiss, 2000).  
 
Figure 1: T-cell Receptor. The most common TCR is a heterodimeric glycoprotein 
composed of one alpha (TCRα) and one beta chain (TCRβ), linked by disulfide bonds 
(Kuwana et al., 1987). Each of these chains has a constant region that recognizes relevant 
signaling molecules, a variable region that contains the binding site for the pMHC complex, a 
charged transmembrane protein that maintains the TCR’s location in the cell membrane, and a 
cytoplasmic tail (Mak & Saunders, 2006b). The constant region and charged transmembrane 
protein of the TCR are noncovalently linked to the CD3 complex, which is composed of 5 
proteins: gamma (γ), delta (δ), and epsilon chain (ε), and two zeta (ζ) chains. Each of these 
CD3 proteins contain an immunotyrosine based activation motif to execute intracellular 
signaling upon TCR antigen recognition. The variable region of each alpha and beta chain 
contains four hypervariable regions which interact with different portions of the pMHC 
complex. Aside from the CD3 complex, T-cell surfaces often house many other invariant 
proteins and protein complexes as well (not shown) (Kuwana et al., 1987; Mak & Saunders, 
2006b). Taken From (Anriar-commonswiki, 2010). 
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Costimulatory receptors on the T-cell surface recognize and bind compatible 
costimulatory surface molecules on antigen presenting cells (APCs) to initiate an 
intracellular signaling cascade. The identity of the costimulatory molecules determines 
whether this cascade inhibits or facilitates T-cell activation. Interaction of the 
costimulatory receptor Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) with its cognate 
costimulatory receptor, for example, inhibits T-cell activation, while the interaction of 
CD28 or CD137 with their respective cognate molecules serves as an essential second 
signal for T-cell activation  (Acuto & Michel, 2003; Valk, Rudd, & Schneider, 2008).  
TC cell activation is typically preceded by TH cell activation, and APC activation. 
When the APC, usually a dendritic cell, presents a specific pMHC unit that is recognized 
by the TH cell, receptor interaction and costimulation results in the activation of both 
cells. The APC is now poised to costimulate the appropriate TC cell, while the TH cell 
secretes cytokines that facilitate TC cell activation. An optimal combination of a strong 
TCR-pMHC binding affinity, costimulation, and TH cell derived cytokine environment 
activates TC cells. The new effector TC cell can now identify and destroy MHC I bound 
foreign peptides in the body (Mak & Saunders, 2006c).  
 
Standard of Care for Treat B-cell Malignancies 
Multiple prognostic factors, such as the classification and clinical staging of a 
cancer, the presence of genetic aberrations, the patient’s age, and the patient’s health 
condition, assist physicians in determining the favorability of a patient’s outcome with 
standard treatments for B-cell malignancies. Typically, younger patients with early-stage,  
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Figure 2: Overview of Chemotherapy Flow. Newly diagnosed patients are typically treated 
with a chemotherapeutic regimen that has been established as the standard of care for the 
condition and stage of the patient’s cancer. If the patient does not achieve a complete remission 
(CR) with first-line therapy, the patient will be treated with an alternative chemotherapy regimen, 
referred to as second-line chemotherapy. Once a complete remission is achieved, patients are 
typically treated with maintenance therapy, to prevent the recurrence of the cancer. If the patient’s 
cancer reemerges (relapses) after previously achieving complete remission, the patient is treated 
with salvage therapy. If a patient fails to achieve CR with second-line chemotherapy or salvage 
therapy, the patient may receive further chemotherapy treatments (not shown), or may proceed to 
receive alternative treatments.  
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localized cancers that lack genetic aberrations have the most favorable prognoses, while 
older patients with disseminated, aggressive disease have the least favorable prognoses. 
Chemotherapy and hematopoietic stem cell transplantation remain the two most 
commonly employed, standard of care treatments for patients diagnosed with B-cell 
malignancies (Döhner et al., 2000; Hilden et al., 2006; Rai et al., 2004). 
 
Table 1. Common Terms in the Discussion of Cancer Therapies 
Complete Remission (Complete 
Response)   
The eradication of all detectible cancer and 
the disappearance of all signs of the disease.  
Complete Response Rate 
The proportion of patients who experience a 
disappearance of the cancer with the 
treatment. Often expressed as a percentage. 
Duration of Response  
The period of time from the documented 
response to therapy, to the time of disease 
progression. 
Event-free survival 
Period of time from the patient’s enrollment 
into the trial, to detectible disease 
progression or the cessation of current 
treatmenta. 
Minimal Residual Disease  
A disease that does not present with any 
morphological signs and symptoms, and can 
only be detected by highly sensitive 
laboratory technology (Hallek et al., 2008; 
S. Lee et al., 2000).  
 
Objective Response Rate (ORR) 
The proportion of patients whose cancer 
diminishes by a predefined amount with the 
treatment. Often expressed as a percentage. 
Overall Survival (OS) 
Period of time from the patient’s enrollment 
into the trial, to the death of the patient. 
Progression free survival  
Period of time from the patient’s enrollment 
into the trial, until detectible disease 
progression or death of the patient. 
Progressive Disease (PD) 
A state in which the cancer continues to 
grow. 
Primary Refractory Cancer 
Cancer that does not respond to, or is 
resistant to, one or more therapeutic agents, 
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Patients diagnosed with B-cell malignances are often treated with an initial course 
of chemotherapy intended to induce a complete remission (CR) in the patient, commonly 
referred to as induction therapy (figure 2). The success of most cancer therapies are often 
discussed in terms of the presence of the disease (table 1). Chemotherapeutic regimens 
are tailored to the patient’s disease type, extent of malignancy, and health status, among 
other factors. If the first regimen, known as first-line chemotherapy, fails to induce a 
complete remission of the cancer, the patient may undergo an alternative 
chemotherapeutic regimen, known as second-line chemotherapy. Complete remission 
refers to a state in which the treatment has successfully eradicated the cancer such that 
the cancerous cells are undetectable by conventionally used, highly-sensitive, detection 
methods. A wide array of chemotherapeutic agents are currently in use. These agents may 
be administered either alone as single agent chemotherapy, or in combinations as multi-
agent chemotherapy.  If a patient’s cancer does not respond to chemotherapeutic agents, 
and therefore does not adequately diminish 
with induction therapy.  
Refractory Cancer 
Cancer that does not diminish in severity 
with one or more therapeutic agents. 
Relapsed Cancer 
Disease that has reemerged after the patient 
has achieved a complete remission with 
previous therapy. 
Relapsed and Refractory Cancer 
Cancer that has reemerged after the patient 
has achieved a complete remission with 
previous therapy, and is now resistant/does 
not respond to one or more therapeutic 
agents.  
aTreatment may be discontinued for multiple reasons, such as the need for alternative 
therapies, or patient preference.  
(“NCI Dictionary of Cancer Terms,” n.d.). 
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it is said to be refractory. A cancer may be refractory to one or more therapeutic agents 
(Friedberg, 2008; Lister et al., 1978). 
Patients who achieve CR are treated with maintenance chemotherapy to prevent 
the reemergence of the cancer. If a patient experiences a revival of the disease after 
achieving complete remission with chemotherapy, the patient’s cancer is said to have 
relapsed. In some cases, the patient’s relapse is caused by the cancer developing a 
resistance to therapeutic agents. In this event, the cancer is referred to as relapsed and 
refractory cancer. Patients who have relapsed are treated with salvage therapy to 
eradicate the relapsed disease.  Salvage chemotherapy may also be referred to as  “third-
line” or “fourth-line” chemotherapy (Gökbuget et al., 2012; Sud & Friedberg, 2008) 
Monoclonal antibodies, such as rituximab, an antibody against the B-cell 
costimulatory molecule CD20, are gaining popularity as effective therapies against B-cell 
malignancies. These immunotheraputic agents may be administered alone, or alongside 
chemotherapeutic agents in a chemoimmunotherapy regimen. Chemoimmunotherapy is 
currently used  as first-line, second-line, maintenance, and salvage therapy regimens, and 
has successfully prolonged the lives of many patients diagnosed with B-cell malignancies 
(Brusamolino, 2009; Dotan, Aggarwal, & Smith, 2010). 
In spite of recent advances in the development of novel therapeutic agents, the 
only truly curative, non-experimental therapies in use for the treatment of B-cell 
malignances are hematopoietic stem cell transplants (HSCTs). In HSCTs, healthy 
hematopoietic stem cells administered to the patient engraft (settle) in the patient’s bone 
marrow, and restore healthy bone marrow function and normal hematopoiesis in the 
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patient. Stem cells can either be derived from a donor (allogeneic), or from the patient 
(autologous) (Gratwohl et al., 2003). HSCTs are associated with severe, potentially fatal 
adverse events, and are consequently considered high-risk procedures, with limited 
patient eligibility (Cornelissen & Blaise, 2016). 
Prior to receiving allogeneic or autologous HSCTs, patients are treated with 
intense regimens of chemotherapy to decrease the patient’s tumor burden, and impair the 
patient’s immune mechanisms. The intense pre-treatments are very physically taxing, 
which further increases the danger of this already high-risk therapy, especially in elderly 
patients. As such, HSCTs are primarily explored as therapeutic options for young, fit 
patients (Wildes, Stirewalt, Medeiros, & Hurria, 2014). 
Stem cells for autologous HSCTs are collected from the patient during a period of 
complete remission. Patients with large tumor burdens or refractory disease may fail to 
achieve remission with conventional therapies, and are therefore unable to receive 
autologous stem cell transplantation. This same patient group may be denied allogeneic 
hematopoietic stem cell transplants (allo-HSCTs) as well, as greater success is observed 
in patients who have achieved complete remission (Bacher et al., 2012; Doney et al., 
2011).  
Donor derived T-cells in allogeneic stem cells may engraft in the bone marrow, 
expand, and mount an immune response against the cancer, known as the graft-versus-
cancer effect (Kolb, 2008). However, these T-cells are also capable of attacking the 
recipient’s healthy tissues, thereby initiating graft-versus-host disease (GVHD), a 
potentially fatal complication of allo-HSCTs. Another serious complication of allo-
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HSCTs is host-versus-graft disease, wherein the recipient’s immune system mounts an 
attack against the donor graft (Holtan, Pasquini, & Weisdorf, 2014). Though autologous 
HSCTs are not associated with these adverse events, autologous grafts are incapable of 
initiating a T-cell mediated graft-versus-cancer attack (Kuruvilla, 2016).  
Following the allogeneic hematopoietic stem cell transplant (allo-HSCT), patients 
may receive repeated donor lymphocyte infusions, which can be curative for some 
patients (Kubuschok, Held, & Pfreundschuh, 2015). Many B-cell neoplasms in patients 
who are ineligible to receive stem cell transplants, or relapse after the administration of 
one or more stem cell transplants, are considered incurable. Further research is necessary 
to establish a curative treatment for such malignancies (Cornelissen & Blaise, 2016; van 
den Brink et al., 2010). 
 
Adoptive T-cell Therapy 
Immunotherapy is a method of treatment that enhances an individual’s own 
immune system, or utilizes components of the immune system, to eradicate the cancer. 
The objective of T-cell immunotherapy, also referred to as adoptive T-cell (ATC) 
therapy, is to utilize either autologous or allogeneic T-cells to confer the patient’s 
enhanced tumor-fighting abilities. The three most commonly discussed forms of T-cell 
immunotherapy are tumor infiltrating lymphocyte (TIL) therapy, T-cell receptor (TCR) 
therapy, and chimeric antigen receptor (CAR) T-cell therapy.  
Tumor Infiltrating Lymphocyte Therapy: The objective of TIL therapy is to 
harvest, expand, and infuse a patient’s own tumor specific lymphocyte population to 
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eradicate malignancies. By expanding the TIL cell population in-vitro, the cells are able 
to proliferate away from the patient’s immunosuppressive tumor environment. This 
process allows for the repair of dysfunctional cell types, and for the selection of cells with 
the greatest tumor specificity. This therapy does not change the method in which the 
immune response against the malignancy is carried out. Rather, it simply provides the 
patient’s existing anti-tumor immune mechanisms with a greater population of the 
patient’s own cancer-fighting cells, to fuel a more robust immune response. In the typical 
course of this treatment, the patient’s tumor infiltrating lymphocytes (TILs) are harvested 
and expanded in a laboratory. The patient is then treated with chemotherapy and 
interleukin-2 (IL-2) infusions, followed by the infusion of the expanded TIL population 
(Sim et al., 2014). The success of phase I clinical trials was hindered by many patients 
choosing to drop out of the trial due to the intense preparative treatments (Besser et al., 
2013, p.).  
Disadvantages to TIL therapy include potentially fatal adverse events and the high 
cost associated with the therapy, which are common to most ATC trials (Hershkovitz, 
Schachter, Treves, & Besser, 2010).  Additional disadvantages of this approach include 
an inability of the infused cells to persist in-vivo, as well as the lengthy time period 
required for the TIL expansion ex-vivo (Wu et al., 2012).  
TIL therapy has been most extensively studied in chemotherapy-refractory 
metastatic melanoma patients. The results of phase I clinical trials suggest that TIL 
therapy may be a curative therapeutic option for this patient population, though its 
reported success in treating other malignancies is limited (Goff et al., 2010; Hershkovitz 
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et al., 2010). Phase II clinical trials are currently underway to further investigate the 
curative potential of TIL therapy.  
T-Cell Receptor Therapy: TCR therapy is an engineered T-cell therapy in which 
TCR genes encoding for antigen-specific TCRs are transferred to primary T-cells. In 
TCR therapy, T-cells, often TIL cells, with high-affinity, tumor specific TCRs are 
isolated. The genes encoding the selected clone’s TCR alpha and beta chains are then 
transduced into primary T-cells, which are then expanded in-vitro and administered to the 
patient in an infusion (Schmitt, Ragnarsson, & Greenberg, 2009).   
Challenges to the success of this therapy include inconsistent TCR expression in 
the engineered T-cells, an inability of the infused cell population to persist in the patient, 
and an inability to confer stable immunologic memory with this method (L. J. Cooper, 
Kalos, Lewinsohn, Riddell, & Greenberg, 2000; Dossett et al., 2009). This therapy is also 
associated with an increased risk of autoimmunity (Schmitt et al., 2009). 
TCR therapy has primarily been studied in patients with hematologic neoplasms, 
with varying rates of success (Cavalieri et al., 2003).  As investigations to enhance the 
safety and efficacy of this therapy continue, the anticipated success of TCR therapy’s 
curative potential continues to grow.  
Chimeric Antigen Receptor T-cell Therapy: In CAR T-cell therapy, CD8+ T-cells 
are modified with a transgenic chimeric antigen receptor to produce a high affinity, tumor 
specific, cytotoxic T-cell. Certain tumors are capable of down-regulating their expression 
of human MHC I (HLA class 1), disrupting antigen presentation mechanisms, and 
rendering T-cells anergic, to escape MHC dependent antigen recognition by TCRs 
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(Garrido & Algarra, 2001; R. Singh & Paterson, 2007). These mechanisms of immune 
evasion are less effective against CAR T-cells, thereby conferring CAR T-cell therapy’s 
advantage over TIL and TCR therapies (Zhou & Levitsky, 2012). CAR T-cell therapy 
exploits the cytotoxic nature of CD8+ T-cells, and the MHC independent binding ability 
and recognition of B-cell receptors, to identify and destroy all cells that express a specific 
cell surface marker. The ability of successfully designed CAR T-cells to persist in the 
body confers its advantage over monoclonal antibody immunotherapy, as CAR T-cells 
can potentially provide long-term, in-vivo, immunosurveillance (Davila & Brentjens, 
2013). CAR T-cell therapy has been most extensively studied in B-cell neoplasms, 
namely Acute Lymphoblastic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), 
and various Non-Hodgkin’s lymphomas (NHLs). The results of phase I clinical trials 
indicate that, with further research, CAR T-cell therapy may be truly curative for patients 
with very advanced, high-risk B-cell neoplasms.  
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Goals 
As a “hot-topic” of research today, the results of CAR T-cell therapy preclinical 
studies and clinical trials continues to be published often, thereby preventing this thesis 
from providing a completely comprehensive overview of the most current research in this 
field. However, the intent of this thesis is to provide the reader with a greater 
understanding of the reasons for CAR T-cell therapy’s esteemed reputation in cancer 
research.   
1) The first goal of this thesis is to provide the reader with a brief overview of the 
current methods of treating B-cell malignancies, and impress, upon the reader, 
the need for novel treatment modalities.  
2) The second goal of this thesis is to provide an in-depth overview of current 
literature to characterize the various steps involved in designing, producing, 
and administering CAR T-cell therapy, and to illuminate points of discourse 
and areas of improvement within each of these steps.   
3) A thorough investigation into the results of published clinical trials is presented to 
place, in context, the current significance of CAR T-cell therapy in the 
treatment of B-cell malignancies.  
4) The final goal of this thesis is to evaluate the curative potential, and anticipated 
role of CAR T-cell therapy in the treatment of B-cell malignancies in the 
future.  
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THE STRUCTURE, DESIGN, PRODUCTION, AND ADMINISTRATION 
OF CAR T-CELLS 
 
CAR T-cell Structure 
The chimeric antigen receptor is so named because its components are derived 
from both antibodies and TCRs. Kuwana et al. published the first design of CAR T-cells 
composed of anti-tumor, antibody-derived single chain variable fragments (scFVs), 
coupled with a transcellular hinge domain, and a single TCR derived CD3ζ signaling 
domain in donor derived TH cells (Kuwana et al., 1987). Subsequent designs of first-
generation CAR T-cells utilized CD3γ, rather than CD3ζ, signaling domains, in TC cell 
substrates, but continued to include a single extracellular recognition region coupled with 
a single intracellular signaling region (Eshhar, Waks, Gross, & Schindler, 1993; Gross, 
Waks, & Eshhar, 1989).   
The recognition of the important role of costimulatory molecules in T-cell 
activation inspired the design of second (figure 3), third, and fourth generation CAR T-
cells, which contain one, two, and three costimulatory domains, respectively, in addition 
the first generation CAR T-cell construct (Finney, Akbar, & Lawson, 2004; Imai et al., 
2004; Pulè et al., 2005a; J. Wang et al., 2007).  Though second generation chimeric 
antigen receptors (CARs) are currently the most extensively studied CARs in clinical 
trials thus far, clinical trials are currently being conducted to evaluate the safety and 
clinical efficacy of third and fourth generation CAR T-cells.  
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Figure 3: Diagram of Second Generation CAR T-cells. Second generation CARs are 
composed of antibody-derived scFVs, a hinge transmembrane domain, a T cell-derived 
intracellular CD3ζ domains, as well as a single costimulatory domain (Finney et al., 2004; Imai 
et al., 2004). Reprinted from Molecular Oncolytics, Vol 3, Wang, Xiuyan, Clinical 
Manufacturing of CAR T Cells: Foundation of a Promising Therapy, 16015., 2016, with 
permission from Elsevier. 
 
 
Designing CAR T-cells  
The success of CAR T-cell therapy is entirely dependent on the ability of the CAR T-
cells to target and destroy the cancer with minimal additional damage to the patient’s 
health. Therefore, it is critically important, when designing CARs, to ensure that: 
1) The CAR specifically recognizes and targets cancer cells (on-target effect).  
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2) The CAR T-cells are capable of being effectively activated. 
3) The CAR T-cells are capable of proliferating and persisting in the patient’s 
body for long periods of time. 
4) The engineered T-cells are capable of stably and reliably expressing the CAR.  
In theory, it is possible to create a CAR against any cell surface molecule, with 
the understanding that any cell expressing that marker will be destroyed. With this 
knowledge, it is crucial to select a target that is maximally expressed on cancer cells, and 
minimally expressed on healthy tissues. CAR T-cells currently being studied in most 
phase I and IIa clinical trials for B-cell malignancies recognize the CD19 cell surface 
molecule, which is only expressed on malignant and benign cells of the B-cell lineage. 
These cells are referred to as anti-CD19 CAR T-cells  (Brentjens et al., 2011, 2013; 
Davila et al., 2014; Kochenderfer et al., 2010, 2012, 2013, 2015; Kusenda & Kovarikova, 
2016; Porter et al., 2013, 2015; Porter, Levine, Kalos, Bagg, & June, 2011; Schuster et 
al., 2015).  
The incorporation of one or more costimulatory molecules into the CAR T-cell 
structure is intended to enable adequate T-cell activation, to achieve an effector response 
capable of eradicating the patient’s cancer. CD137 (4-1BB) and CD28 are the most 
commonly utilized costimulatory domains in CAR T-cell design. In second generation 
CAR T-cells, which have only one costimulatory domain, the superiority of these 
domains continues to be disputed. Preclinical models reveal that CD28 coupled CAR T-
cells have greater anti-tumor effects against B-cell Acute Lymphoblastic Leukemia (B-
ALL) (Posey et al., 2013). Other preclinical studies propose that CD28 coupled CAR- 
 20 
cells are more likely to trigger rises in IL-2 and tumor necrosis factor-α (TNF-α) levels, 
compared to CD137 coupled CAR T-cells, thereby causing natural regulatory T-cell 
mediated-inhibition against the CAR T-cells’ effector functions (D. W. Lee et al., 2014).  
Progressive generations of CAR T-cell models, incorporating two or three costimulatory 
domains, are designed to improve CAR T-cell activation and function.  
Maximizing proliferative potential and minimizing T-cell exhaustion are critical 
factors in prolonging T-cell persistence in-vivo. Most phase I clinical trials to date 
selected for CD3+ T-cells, which consists of many different T-cell subsets (Kalos et al., 
2011; Kochenderfer et al., 2010; Savoldo et al., 2011). However, new evidence suggests 
that cytotoxic effector T-cells, TCM cells, TEM cells, and naïve T-cells are not equal in 
their ability to resist T-cell exhaustion. Therefore, the selection of the correct T-cell type 
to undergo genetic modification is important in conferring CAR T-cell persistence (C. 
Berger et al., 2008; Klebanoff et al., 2005). Utilizing TCM cells or naïve memory T-cells 
will impart greater persistence and proliferative advantages to the engineered T-cells in-
vivo (Hinrichs et al., 2009, 2011; Nguyen et al., 2016). Other methods to enhance T-cell 
activation are employed in the manufacturing process (C. Berger et al., 2008; Hinrichs et 
al., 2009, 2009, 2011). 
 
Manufacturing CAR T-cells  
Leukocytes are first collected through a process called leukapheresis, wherein 
peripheral blood mononuclear cells are taken from a sample of the blood, and the 
remainder of the blood is returned to the patient. If the leukocytes are derived from the 
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patient who will later receive the CAR T-cell infusion, the product is autologous. If a 
donor contributes these cells, the resulting product is allogeneic. The existence of 
harvestable T-cells is, therefore, a prerequisite for creating CAR T-cells.  Physicians 
schedule leukapheresis per the patient’s other treatments to ensure that the patient’s 
lymphocyte population is sufficiently large enough to harvest.  
 
Figure 4: Autologous CAR T-cell Manufacturing. Leukapheresis is used to obtain white 
blood cells from the patient (step 1) (Xiuli Wang et al., 2016). The leukapheresis product is then 
subjected to counterflow centrifugal elutriation (Step 2) (Powell et al., 2009) and 
immunomagnetic selection beads (not shown) to enrich for specific T-cell phenotype(s) (Xiuyan 
Wang & Rivière, 2016). The selected T-cells are then activated with antibody-coated beads (step 
3) (Porter et al., 2006) before genes encoding the CAR design are transferred to the T-cell 
substrate by viral vectors (step 4), transposon/transposase system (not shown), or mRNA transfer 
(not shown) (Cartellieri et al., 2014). The genetically modified T-cell population then expands in 
a bioreactor (step 5). Following the washing and concentration of the newly expanded CAR-T 
cell population (step 6), the product is subjected to quality control measures (step 7), before being 
cryopreserved and shipped to the patient’s treatment location (step 8). The thawed CAR T-cell 
product is then intravenously administered to the patient. Reprinted by permission from 
Macmillan Publishers Ltd on behalf of Cancer Research UK: Nature Reviews (Fesnak, June, & 
Levine, 2016). 
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The product of leukapheresis contains a combination of leukocytes, including B-
cells, T-cells, and APCs, among other white blood cell types. Lymphocytes are 
commonly enriched by counterflow centrifugal elutriation, which exploits the difference 
in cell sizes to select for lymphocytes in the leukapheresis product (Banfalvi, 2008; 
Powell et al., 2009). Specific subsets of T-cells, most commonly CD3+ T-cells, are then 
enriched for by either positive or negative immunomagnetic selection beads (Zhu et al., 
2016). Bead-based systems to specifically select for TCM cells and naïve T-cells have also 
been established (Casati et al., 2013; Xiuli Wang et al., 2012). The enriched T-cell 
population is then capable of undergoing the downstream activation steps, or may be 
cryopreserved for future use (Campbell et al., 2015; Xiuyan Wang & Rivière, 2016).   
Many biotechnology companies have facilitated the use of beads-based T-cell 
activation, namely antibody coated magnetic beads and antibody coated nanobeads, as 
common methods of T-cell activation (Cartellieri et al., 2014; Terakura et al., 2012, p. 
19). Antibody coated magnetic bead systems covalently couple superparamagnetic, APC-
sized, inert beads to antibodies. Anti-CD3 and anti-CD28 antibodies, involved in signal 1 
and signal 2 of T-cell activation, respectively, are most often utilized in beads-based 
activation of CD3+ T-cell populations. This system simultaneously allows for the 
selection and the activation (steps 2 and 3, figure 4) of the desired T-cell population 
(Smith et al., 2015). These beads must be removed prior to continuing with the 
downstream steps in CAR T-cell manufacturing process (Matheson, Peden, & Lehner, 
2014). Antibody coated nanobeads use a biodegradable polymeric nanomatrix coupled to 
anti-CD3 and anti-CD28 antibodies to activate T-cells using the same process as the 
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antibody coated magnetic beads described above. The biodegradable nature of these 
nanobeads confers their primary advantage - they do not need to be removed prior to 
continuing with the downstream steps in the manufacturing process (Casati et al., 2013).   
Genes encoding the chimeric antigen receptor must then be transferred into the 
selected T-cell substrate population. Gamma retroviral transduction and lentiviral 
transduction are the two most commonly used methods of gene transfer in CAR T-cell 
production. However, transposon/transposase systems are gaining popularity as the 
potential for mainstream administration of CAR T-cell therapy becomes an increasingly 
realistic goal. The objective of choosing one of these three methods is to efficiently 
transfer CAR encoding genes, and to ultimately produce a T-cell that is capable of stable 
CAR expression (Cartellieri et al., 2014).  
Gamma retroviral transduction is the most extensively studied method of gene 
transfer in engineered T-cells. Unlike lentiviral transduction, gamma retroviral vectors 
are only capable of transducing dividing cells. Both gamma retroviruses and lentiviruses 
are retroviruses, and therefore contain a ribonucleic acid (RNA) genome (Yi, Jong Noh, 
& Hee Lee, 2011). In retroviral transduction, scientists create vectors with RNA genomes 
encoding for the desired CAR. When the virus enters the T-cell, its RNA genome is 
reverse transcribed to generate deoxyribonucleic acid (DNA) that viral integrase enzymes 
then insert into the cellular genome. The T-cell is now capable of encoding and 
expressing the CAR (Cepko & Pear, 2001). Although retroviral transduction has proven 
largely successful, potential genotoxicity and insertional mutagenesis resulting from 
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genomic integration, particularly genomic integration into known cancer related genes, 
remains a concern (Field et al., 2013; Q. Liu et al., 2015).  
Transposon/transposase systems are currently being investigated to improve gene 
transfer rates in CAR T-cell production. This system involves the transfection, non-viral 
introduction via electroporation or lipotransfection, of DNA into the T-cell, which poses 
less immunogenic risk than viral transduction, to induce stable CAR expression (Monjezi 
et al., 2016). In the “sleeping beauty” (SB) transposon system, the CAR encoding DNA 
transposon, a sequence of synthetic DNA that is capable of changing its position in a 
genome, is introduced into the cell. The SB transposase enzyme inserts the transposon 
randomly into the T-cell genome in a “cut-and-paste” manner (Ivics, Hackett, Plasterk, & 
Izsvák, 1997). Notably, this random integration results in a potential mutagenic risk, and 
it therefore poses a potential oncogenic risk as well. Utilizing mRNA-derived transposase 
and supercoiled DNA vectors, known as “minicircles,” instead of plasmids, as the 
transposon’s source increases gene transfer rates while decreasing T-cell toxicity. 
Minicircles also have the benefit of lacking antibiotic resistance genes (Monjezi et al., 
2016). Studies have also shown success using the “piggyBac” transposon/transposase 
system as an alternative to the SB system (Manuri et al., 2010). Further investigations are 
necessary to establish the clinical efficacy and safety of SB and “piggyBac” 
transposon/transposase systems in CAR T-cell production.   
After successful retrovirus-mediated gene transfer, CAR T-cell expansion most 
commonly occurs in a bioreactor (Themeli, Rivière, & Sadelain, 2015).  CAR T-cells 
produced by transposon/transposase gene transfer must be expanded by recursive 
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artificial APC (aAPC) stimulation, where an environment of artificial APCs (aAPCs), 
cytokines IL-2 and interleukin-21 (IL-21), and cells expressing a variety of costimulatory 
molecules enhance the population’s expansion (Suhoski et al., 2007).  
 
Table 2: Quality Release Tests for CAR T-cells Based on Method of Gene Transfer 
Parameter Concerns Retroviral Gene 
CAR T-cell 
Products 
Transposon/Transposase 
System CAR T-cell 
Products 
Safety Presence of harmful 
agents in final product. 
• Mycoplasma 
• Sterility 
• Replication-
competent 
retrovirus or 
lentivirus 
• Endotoxins 
• Aberrant 
transgene 
insertion 
 
• Mycoplasma 
• Sterility 
• Endotoxins 
 
Purity Abundance of unwanted 
remnants of the patient’s 
initial leukapheresis 
sample and/or the 
manufacturing processes. 
• CAR T-cells % 
• non-CAR T-
cells % 
• Residual Tumor 
Cells 
• Activation 
and/or Selection 
Beads 
• CAR T-cells % 
• non-CAR T-cells % 
• aAPCs 
 
 
Identity Percentage of CAR T-
cells, in comparison to 
other undesired 
components, in the bulk 
product. 
CAR T-cells % CAR T-cells % 
Potency Cytotoxic potential of the 
newly engineered CAR 
T-cells. 
• In-vitro 
cytotoxic 
lymphocyte 
assay 
• IFN-γ secretion 
assay 
 
• In-vitro cytotoxic 
lymphocyte assay 
• IFN-γ secretion assay 
 
Source (Xiuyan Wang & Rivière, 
2016). 
(Hollyman et al., 
2009). 
(H. Singh, Huls, Kebriaei, 
& Cooper, 2014). 
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While various quality control measures are built into every step of the 
manufacturing process, the product after expansion is washed and concentrated, then 
subjected to quality release testing. Such tests typically evaluate the safety and purity of 
the T-cell product (table 2). Once quality release tests are completed, the CAR T-cell 
product is cryopreserved and transported to the patient’s site of care. The entire process 
of manufacturing CAR T-cells can be completed in 5-10 days (Fesnak et al., 2016). 
 
 
Administering CAR T-cell Infusions 
Physicians may choose to provide patients preparative, lymphodepleting 
chemotherapy prior to the CAR T-cell infusion. The importance of pre-treatment 
continues to be disputed in current literature (Brentjens et al., 2011; Gattinoni et al., 
2005). A general point of concern when pre-treating patients with chemotherapy is the 
difficulty in discerning if, and to what extent, the patient’s response is caused by the 
chemotherapy, or the engineered T-cell infusion. However, many groups have suggested 
an inverse relationship between tumor burden and the success of CAR T-cell therapy. 
Therefore, pre-treating patients with chemotherapy may decrease the patient’s tumor 
burden prior to the CAR T-cell infusion thereby enhancing the efficacy of CAR T-cells in 
the patient (Davila & Brentjens, 2013; Kochenderfer et al., 2012). Yet, chemotherapy-
refractory patients, by definition, will not receive substantial benefits from pre-treatment. 
Many groups have reported that preparative chemotherapy had little to no effect on the 
tumor burdens of relapsed and/or refractory patients with B-cell neoplasms prior to the 
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CAR T-cell infusion (Kalos et al., 2011; Kochenderfer et al., 2012; Porter et al., 2015, 
2011). Additionally, complete responses have been achieved in patients who did not 
receive chemotherapy, indicating that the outcomes of CAR T-cell therapy may not be 
enhanced by preparative treatment (Grupp et al., 2013; Kochenderfer et al., 2013). 
Further investigations aimed at establishing the effects of preparative chemotherapy, and 
a standard regimen of pre-treatment, have yet to be performed.  
The cryopreserved CAR T-cell product is thawed and intravenously infused into 
the patient’s blood stream. The infusion process can take up to four weeks, and must be 
tailored to each individual patient’s current treatment regimen (Turtle et al., 2016). The 
first few weeks post-infusion are characterized by rapid activation and proliferation of the 
CAR T-cells in the patient’s body. Patients experience most cytokine related adverse 
events during this time, with the greatest severity of complications occurring at the peak 
of the CAR T-cell population’s expansion. Varying correlations between the persistence 
of CAR T-cells in-vivo and the extent of B-cell malignancy eradication have been 
reported in phase I clinical trials. In practice, widely accepted guidelines indicating 
clinically appropriate dosages of CAR T-cells have not been established. There is 
evidence to suggest that the dose of infused CAR T-cells should be altered per the 
patient’s tumor burden after pre-treatment (Davila & Brentjens, 2013; Kochenderfer et 
al., 2012). 
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COMMON ADVERSE EVENTS IN THE COURSE OF CAR T-CELL 
THERAPY 
While design and manufacturing processes impart significant risks to CAR T-cell 
therapy for B-cell malignancies, the most significant adverse events reported in phase I 
clinical trials are related to elevations in cytokine levels following CAR T-cell infusion 
(figure 5). The most commonly observed adverse events following CAR T-cell infusion 
are cytokine release syndrome (CRS), macrophage activation syndrome (MAS), 
neurological toxicities, tumor lysis syndrome, and B-cell aplasia.  
 
Cytokine Release Syndrome  
Most patients experience CRS to some degree following CAR T-cell infusion. The 
activation and proliferation of T-cells after the infusion results an elevation in the levels 
of circulating cytokines that causes the systemic inflammatory response known as CRS. 
T-cell activation and proliferation are necessary mechanisms in ensuring T-cell 
persistence and efficacy (Fitzgerald et al., 2016; D. W. Lee et al., 2014). Though 
laboratory markers cannot be reliably used to diagnose CRS, high levels of C-reactive 
protein (CRP) and ferritin may be observed, along with drastic elevations in cytokine 
levels (Barrett, Teachey, & Grupp, 2014; Davila et al., 2014; Klinger et al., 2012).  
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Figure 5: Potential Risks and Common Complications of CAR T-cell Therapy. 
Though rarely observed in CAR T-cell patients to date, insertional oncogenesis and anaphylaxis 
are notable risks of the CAR T-cell manufacturing process. The gene-transfer step in CAR T-cell 
production has the potential to disrupt genetic material and/or gene structure, causing harmful 
mutagenesis (Sadelain, 2004). Mouse-derived CAR genes and/or the novel structure of 
recombinant proteins may stimulate an immune response against the infused cells, further 
damaging the patient’s health (Maus et al., 2013). On-target, off-tumor toxicity occurs when the 
CAR T-cell target is expressed on healthy tissues, which are then attacked and damaged by the 
CAR T-cells. In anti-CD19 CAR T-cell therapy, the destruction of the CD19-expressing cell 
population leads to B-cell aplasia. CRS is the most common adverse event following CAR T-cell 
infusion. Many, though not all, neurological toxicities are symptoms of CRS. The onset CRS and 
many neurological toxicities correlate temporally with the peak of T-cell expansion following 
CAR T-cell infusion (Fitzgerald et al., 2016). Taken from (Bonifant, Jackson, Brentjens, & 
Curran, 2016). 
 
Patients may exhibit symptoms of CRS hours to days after CAR T-cell infusion. CRS 
has a heterogenous presentation, and patients may exhibit a wide array of symptoms from  
high fever to organ failure, that range in severity from mild to fatal (Roskos, Davis, & 
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Schwab, 2004). Regardless of the severity of CRS, patients are typically hospitalized for 
observation and treatment (Fitzgerald et al., 2016; Maude, Teachey, Porter, & Grupp, 
2015). Careful surveillance of the patient’s condition and immediate treatment of 
cardiovascular dysfunction and respiratory distress is critical in the treatment of severe 
CRS. The ultimate objective of treating CRS is to minimize life-threatening, toxic 
symptoms without interfering with mechanisms of T-cell activation and proliferation (D. 
W. Lee et al., 2014). 
Tocilizumab, an antibody that blocks the receptor of the pro-inflammatory cytokine 
interleukine-6 (IL-6), has been proven to successfully treat CRS related fever and blood 
pressure changes over a period of 1-3 days. Tocilizumab can potentially inhibit T-cell 
activation and proliferation, though this has not yet been proven in a clinical study 
(Maude et al., 2015). Tocilizumab may also hinder the recognition and treatment of MAS 
(Shimizu et al., 2012). Consequently, the administration of tocilizumab is restricted to 
severe CRS cases. Corticosteroids, which are commonly used to treat shock and sparingly 
used to treat severe CRS, can successfully reverse CRS symptoms, but have the 
documented effect of eliminating the CAR T-cell population over time (Davila et al., 
2014; Kochenderfer et al., 2013; Maude, Barrett, Teachey, & Grupp, 2014). In life 
threatening CRS cases, patients may be treated with immunosuppressive therapy at the 
expense of the CAR T-cells’ viability, leading to a relapse of the cancer (Maude et al., 
2015).  
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Macrophage Activation Syndrome 
MAS is primarily recognized as a potentially fatal condition resulting from 
systemic inflammatory disorders, particularly in pediatric patients. Patients suffering 
from MAS often exhibit high fevers, enlargement and/or insufficiencies of the liver and 
spleen, deficiencies in blood cells (pancytopenia), coagulopathy, and neurological 
toxicities. Similar to CRS, MAS is the byproduct of cytokine elevations produced by 
rapid T-cell activation and proliferation. In the context of CAR T-cell therapy, CRS is 
often discussed as transforming into MAS (Grupp et al., 2013). The finding that both 
MAS and CRS produce similar cytokine elevation profiles supports this assertion (Maude 
et al., 2015; Teachey et al., 2013, 2016). However, investigators have yet to establish a 
concrete relationship between CRS and MAS in the context of CAR T-cell therapy.   
 
Neurological Toxicities 
Following CAR T-cell infusions, patients may present with a number of 
neurologic toxicities. The most commonly occurring encephalopathies include confusion 
and loss of alertness (obtundation) (Fitzgerald et al., 2016; Kochenderfer et al., 2015). 
These neurological toxicities present later than septic shock-associated encephalopathies, 
and are believed to be related to the patient’s CRS, although it should be noted that pre-
treatment with tocilizumab did not prevent the incidence of neurotoxic events. In most 
cases, these neurotoxic events are low-grade and self-limiting (Fitzgerald et al., 2016).  
Severe neurological toxicities are less commonly observed in patients receiving CAR T-
cell therapy, but may include seizures, an inability to speak or to comprehend speech 
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(aphasia), muscle twitches, and unilateral facial paralysis, among other complications. In 
a select few cases, severe neurological toxicities were found to be caused by CAR T-cells 
penetrating the blood-brain-barrier to reside in the cerebral spinal fluid (Hu et al., 2016). 
However, the cause for most of observed encephalopathies, both mild and severe, 
following CAR T-cell infusions remains unknown (Davila et al., 2014; Fitzgerald et al., 
2016; Kochenderfer et al., 2012, 2015).  
 
Tumor Lysis Syndrome  
 Tumor lysis syndrome, a common complication of many hematologic cancer 
therapies, occurs when numerous tumor cells release their contents upon destruction. 
Patients often present with a variety of metabolic abnormalities ranging from mild to fatal 
in severity, shortly after the therapy takes effect. The severity of tumor lysis syndrome is 
positively correlated to the patient’s tumor burden. In managing tumor lysis syndrome, 
maintaining proper renal function and preventing cardiac and neuromuscular dysfunction 
is of critical importance (Howard, Jones, & Pui, 2011). In CAR T-cell therapy trials, 
cases of tumor lysis syndrome were typically observed when CAR T-cell populations 
peaked in-vivo (Grupp et al., 2013).  
 
B-cell Aplasia 
The primary objective of treating B-cell neoplasms with B-cell targeting CAR T-
cells is to eliminate cancerous B-cells by eradicating the patient’s entire B-cell 
population. Therefore, B-cell aplasia, the absence of B-cells, is an expected result of 
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successful anti-CD19 CAR T-cell therapy that correlates with the infused cells’ 
persistence and potency in-vivo. Sufficiently potent anti-CD19 CAR T-cells eliminate the 
plasma cell population as well, resulting in a state of insufficient antibody production 
known as hypogammaglobulinemia. Though B-cells are important components of the 
body’s immune system, B-cell aplasia is a manageable condition that is treated with 
infusions of antibody precursors known as gamma globulins (Dai, Wang, Lu, & Han, 
2016).  
 
 
THE RESULTS OF SECOND GENERATION, ANTI-CD19 CAR T-CELL 
THERAPY PHASE I AND IIA CLINICAL TRIALS IN PATIENTS DIAGNOSED 
WITH B CELL MALIGNANCIES  
Second generation, anti-CD19 CAR T-cells are the most extensively studied CAR 
T-cell construct in clinical trials for patients with B-cell neoplasms. Most phase I and IIa 
studies with this T-cell design have been conducted in populations of patients diagnosed 
with high-risk, relapsed and/or refractory B-cell malignancies, for which no curative 
treatment options were available. Anti-CD19 CAR T-cells have shown the greatest 
curative potential in B-cell Acute Lymphoblastic Leukemia (B-ALL) patients, with 
notable success in treating B-cell Chronic Lymphocytic Leukemia (B-CLL), B-cell Non-
Hodgkin’s Lymphomas (B-NHL, lymphomas that do not express Reed Sternberg cells), 
and Multiple Myeloma.  
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Acute Lymphoblastic Leukemia 
B-ALL is a neoplasm of B lymphocyte precursors, known as lymphoblasts, that 
typically affects children. While most ALL patients are diagnosed with precursor B 
neoplasms, 15-20% of patients are diagnosed with precursor T-cell neoplasms (S. L. 
Cooper & Brown, 2015; Hochberg, El-Mallawany, & Cairo, 2014; Shustov, 2012). 
Newly diagnosed B-ALL is typically associated with a favorable prognosis in 
children; approximately 95% of pediatric patients achieve complete remission with 
standard therapies. However, B-ALL is associated with very poor prognoses in newly 
diagnosed adults, as well as in patients of all ages diagnosed with relapsed and/or 
refractory disease (Benjamin & Stein, 2016; Ottmann et al., 2007; Pui & Evans, 2006; 
Raetz & Bhatla, 2012; Thomas et al., 2010). Allo-HSCT is considered the only curative 
treatment for patients who fail to achieve sustained complete remissions with 
blinatumomab (anti-CD19 monoclonal antibody) incorporated chemoimmunotherapy, 
although eligibility for this treatment is limited. B-ALL that has relapsed or fails to 
adequately respond to allo-HSCT is considered incurable (Doney et al., 2011; Maude, 
Frey, et al., 2014).  
Phase I clinical trials investigating the effects of second generation anti-CD19 CAR 
T-cell therapy have yielded successful results in treating children and adults with B-ALL 
(table 3). Nearly every patient in these clinical trials experienced CRS and B-cell aplasia  
(Brentjens et al., 2011, 2013; Dai et al., 2015; Grupp et al., 2013; Maude, Frey, et al., 
2014)(Grupp et al., 2013; Maude, Frey, et al., 2014). Although preclinical studies showed 
more potent anti-leukemic effects of CD137 coupled anti-CD19 CAR T-cells in the 
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eradication of B-ALL, both CD137 expressing CAR T-cells and CD28 expressing CAR 
T-cells have been studied extensively in clinical trials. 
 
Table 3. Summary of Phase I Clinical Trials for Second Generation, Anti-CD19 
CAR T-cell Therapy in Patients Diagnosed with B-ALL 
Publication Trial Location Number of 
patients 
Costimulatory 
Molecule 
Complete 
Response 
Rate 
Longest 
Duration of 
CR  
(Grupp et al., 
2013) 
UPenn 2 CD 137 (4-
1BB) 
100% 11+ months 
(Maude, Frey, 
et al., 2014) 
UPenn 30 CD 137 (4-
1BB) 
90% 24+ months 
(Brentjens et 
al., 2013) 
MSKCC 5 CD28 100% N/R a 
(Davila et al., 
2014) 
MSKCC 16 CD28 88% N/R a 
(D. W. Lee et 
al., 2015) 
NCI 20 CD28 70% 5+ months 
a Patients who achieved complete remission went on to receive allo-HSCT.  
Not Reported (N/R). University of Pennsylvania (UPenn). Memorial Sloan Kettering Cancer Center 
(MSKCC). National Cancer Institute (NCI). 
 
Most adult patients enrolled in these trials were diagnosed with either relapsed 
and/or drug-refractory (chemotherapy-refractory and/or blinatumomab-refractory) 
disease, while children enrolled in these studies were diagnosed with relapsed and/or 
drug-refractory disease, or relapsed disease after receiving allo-HSCT (Grupp et al., 
2013; Maude, Frey, et al., 2014). Unlike the childhood B-ALL investigations, where 
CAR T-cell therapy is explored as a curative option in children whose cancer relapsed 
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after receiving allo-HSCT, the objective of CAR T-cell therapy in an adult population is 
to prepare patients to receive allo-HSCT (Brentjens et al., 2013). 
In children who have previously undergone allo-HSCT, the patient-derived T-cell 
substrates are of the donor’s lineage, and are therefore considered allogeneic. 
Interestingly, none of the patients who received these allogeneic CAR T-cells, as the 
result of having undergone an HSCT in the past, developed GVHD (Grupp et al., 2013; 
Maude et al., 2015). However, a study investigating donor-derived CAR T-cells in adult 
B-ALL patients found that CAR T-cells engineered from T-cells directly derived from 
the donor, rather than patient-derived donor lymphocytes, are capable of causing GVHD 
(Dai et al., 2015). 
Patients with higher disease burdens at the time of the engineered T-cell infusion 
experienced more severe CRS, which typically progressed to MAS (Brentjens et al., 
2011; Fitzgerald et al., 2016; Grupp et al., 2013). A small number of patients experienced 
encephalopathy as well. Though every patient in these studies achieved B-cell aplasia, 
Maude et al. reported prolonged B-cell aplasia lasting more than a year after CAR T-cell 
clearance in their large population of both children and adult relapsed and refractory ALL 
patients (2014). In contrast, Brentjens et al.’s results show an increase in normal B-cell 
lymphopoiesis associated with the decline of the CAR T-cell population (2011). The 
difference in these results cannot be attributed to the CAR T-cell design, as both studies 
utilized CD19-28z CAR T-cells.  
Following CAR T-cell infusion, CAR T-cells were found in the cerebrospinal 
fluid (CSF) of twenty-one patients across two clinical trials. Only 2 of these patients were 
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diagnosed with central nervous system (CNS) leukemia prior to the modified T-cell 
infusion (Grupp et al., 2013; Maude, Frey, et al., 2014). Although central nervous system 
(CNS) involvement is relatively uncommon in B-ALL, it is responsible for 6% of B-ALL 
relapses. The 1-10% of B-ALL patients with CNS involvement are considered part of the 
high-risk B-ALL group who often undergo intrathecal therapy (medications administered 
directly into the spinal canal), cranial irradiation, and allo-HSCTs (Lazarus et al., 2006). 
The finding of CAR T-cells in the CSF is therefore significant, as their presence may 
impart immune protection in the CNS, thereby preventing the relapse of B-ALL in the 
CNS (Pullen et al., 1993).  This claim is supported by the finding that two patients with 
prior CNS leukemia did not experience a relapse of CNS leukemia after the CAR T-cell 
infusion (Maude, Frey, et al., 2014).  
Most B-ALL relapses in these clinical trials were due to insufficient CAR T-cell 
persistence in-vivo, or due to the emergence of an escape variant. The administration of 
steroids to manage severe CRS symptoms may have caused the diminished persistence of 
CAR T-cells in these patients. Though repeated CAR T-cell infusions were found to 
enhance the persistence in these patients, few patients treated with steroids received this 
protocol (Davila et al., 2014; Maude et al., 2015). Reasons for this include a lack of 
eligibility to receive repeated infusions, personal preference, and/or the trial did not 
examine the effects of repeated CAR T-cell infusions. Relapses unrelated to problems of 
persistence resulted in a CD19- escape variant cancer. It is possible for patients to have 
B-cell precursors that lack CD19 (CD19- precursors). In such cases, though anti-CD19 
CAR T-cells eliminate CD19+ cells, a cancerous CD19- escape variant, related to the 
 38 
original CD19+ lineage, can proliferate and result in a relapse of the cancer (Maude et al., 
2015). 
 The CR rates of the newest FDA approved chemotherapy drugs used to treat B-
ALL are less than 25% (Maude, Frey, et al., 2014). In contrast, the complete remission 
rates of CAR T-cell therapy, reported by these clinical trials, is between 70-100%, with 
documented sustained remissions of up to two years. The results of these studies are 
therefore significant, and suggest that, with further research, CAR T-cell therapy may be 
widely employed as a curative treatment for CD19+ ALL.  
 Multicenter phase I clinical trials, as well as phase IIa clinical trials, are currently 
underway to further investigate the clinical success of CD19 CAR T-cell therapy in B-
ALL patients (Curran et al., 2015).  
 
Chronic Lymphocytic Leukemia 
The most commonly diagnosed adult leukemia, CLL, is a cancer of mature B-
cells (Goldin & Caporaso, 2007; Jemal, Siegel, Xu, & Ward, 2010). Though the 
presentation and clinical course of CLL varies greatly, abnormalities in the structure or 
function lymph nodes (lymphadenopathy) commonly accompany a CLL diagnosis 
(Parikh & Shanafelt, 2016).  
The widespread use of chemoimmunotherapy has greatly improved the overall 
response and progression free survival rates of CLL patients treated with standard of care 
therapies (Thompson et al., 2016). Despite the remarkable success of 
chemoimmunotherapy, disease progression is typically anticipated, and often inevitable. 
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Though allo-HSCT is considered a curative therapy for CLL patients, CLL primarily 
affects elderly patients, many of whom are ineligible for allo-HSCT. As such, CLL is 
widely considered an incurable disease (Rozovski et al., 2015).   
Four major phase I clinical trials have been conducted by various academic 
organizations to investigate the therapeutic effects of second generation anti-CD19 CAR 
T-cell therapy in CLL patients (table 4). Patients enrolled into these studies typically had 
very advanced CLL that failed to respond to multiple other forms of therapy. Most 
patients had refractory CLL, CLL that has relapsed multiple times, and/or CLL with 
chromosomal abnormalities or mutations that rendered their disease aggressive and 
severe (Brentjens et al., 2011; Kalos et al., 2011; Kochenderfer et al., 2012, 2013; Porter 
et al., 2015).  
Studies that treated patients with lymphocyte depleting chemotherapy prior to 
administering the CAR T-cell infusion revealed that reductions in CLL tumor cell 
frequency were either not present or negligible after receiving the preparative 
chemotherapy. Such results ensure that any observed cancer eradication can be attributed 
to the efficacy of CAR T-cells, rather than to the anti-tumor effects of the preparative 
chemotherapy. Every study reported marked reductions in adenopathy, and a significant 
reduction or clearance of CLL in the bone marrow within one month after the infusion, in 
patients who exhibited a clinical response. (Brentjens et al., 2011; Kochenderfer et al., 
2012; Porter et al., 2011). These studies showed that the clearing of the tumor was related 
to engineered T-cell trafficking to tumor sites in the lymph nodes, bone marrow, and liver 
less than 2 days after CAR T-cell infusion (Brentjens et al., 2011).   
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Kochenderfer et al.’s study published in 2013 investigated the outcomes of donor-
derived CAR T-cells in both B-CLL and B-NHL patients whose cancer relapsed after 
allo-HSCT. Only patients who had not developed GVDH, or who had developed only 
mild, grade 1 acute GVDH after receiving a donor lymphocyte infusion, were enrolled in 
this study. T-cells were derived directly from the patient’s lymphocyte transplant donors, 
rather than the patients themselves. Interestingly, although some patients received 
transplants from HLA-matched sibling donors, while other patients received transplants 
from unrelated donors, none of the patients who received the allogeneic CAR T-cell 
infusion developed GVHD (Kochenderfer et al., 2013). 
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Table 4. Summary of Phase I Clinical Trials for Second Generation, Anti-CD19 CAR T-
cell Therapy in Patients Diagnosed with B-CLL 
Publicatio
n 
Trial 
Location 
Number 
of 
patients 
enrolled  
Costimulat-
ory 
Molecule 
Pre-treatm-
ent 
Number of 
patients 
who 
Achieved 
SD 
(longest 
duration 
of SD) 
Number of 
patients 
who 
Achieved 
PR 
(longest 
duration 
of PR) 
Number of 
patients 
who 
Achieved 
CR 
(longest 
duration 
of CR) 
(Brentjens 
et al., 
2011) 
MSKCC 8 CD28 
Group 1: 
Noa 
Group 2: 
Yes 
1 (4+ 
months) 0 0 
(Kochender
fer et al., 
2012) 
NCI 4 CD28 Yes 1 (6 months) 
2 (7+ 
months) 
1 (15+ 
months) 
(Kochender
fer et al., 
2013) 
NCI 4 CD28 No 1 (3 months) 0 
1 (9+ 
months) 
(Porter et 
al., 2015) UPenn 14 CD 137 Yes N/R
b 4 (13+ months) 
4 (53+ 
months) 
aDose escalation study in which group one was treated with dose-escalating CAR T-cell therapy doses without 
preparative chemotherapy, and group 2 was pre-treated with dose-escalating chemotherapy prior to a constant 
dose of CAR T-cell infusion. 
bStable disease status not reported. Four patients are alive with disease. Longest reported duration of patient alive 
with disease is 26 months. 
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Early studies report elevations in cytokine levels and the clinical presentation of 
what is now referred to as CRS. In a study published in 2011, the death of one patient 
within two days after receiving the CAR T-cell infusion was attributed to a possible pre-
existing infection (Brentjens et al., 2011). It is possible that the patient’s symptoms and 
abnormal cytokine profile may have been associated with undiagnosed CRS. Though few 
studies report severe cases of CRS, a better understanding of CRS and the use of 
tocilizumab could have aided these early clinical trials in improving the patient’s CRS 
symptoms and promoting CAR T-cell persistence.  
It was generally observed that the development of CRS resulted in a delayed 
clinical response to the CAR T-cell infusion (Kalos et al., 2011; Kochenderfer et al., 
2013; Porter et al., 2015, 2011). A small number of patients who developed severe CRS 
went on to develop MAS (Porter et al., 2015). 
Notably, two patients in a study conducted at the National Cancer Institute (NCI) 
did not experience any cytokine mediated toxicities. However, neither of these patients 
achieved sustained remissions after receiving CAR T-cell infusions, and both received 
alternative treatments for their progressing CLL (Kochenderfer et al., 2013). CAR T-cells 
were not detected in one of these two patients after infusion, supporting the suggestion 
that some level of CRS is necessary for the proliferation and persistence of the CAR T-
cell population (Davila et al., 2014; Kochenderfer et al., 2013). Other common adverse 
events reported in this study include tumor lysis syndrome and neurologic toxicities. The 
onset of tumor lysis syndrome also further delayed the patient’s clinical response to the 
engineered T-cell infusion (Kochenderfer et al., 2013; Porter et al., 2011). The few 
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documented occurrences of neurologic toxicities were transient, and likely caused by 
CRS-associated high fevers (Porter et al., 2015).  
 Brentjens et al. report that the anti-CD19 CAR T-cell infusion in three of the four 
patients studied greatly reduced the tumor burden and/or lymphadenopathy without the 
onset of B-cell aplasia (2011). However, CAR T-cell therapy failed to induce complete or 
partial remissions in any of these patients, suggesting that B-cell aplasia is a necessary 
anti-leukemic event in the successful course of CAR T-cell therapy (Brentjens et al., 
2011; Nazimuddin et al., 2013). This is supported by Porter et al.’s finding that long term 
B-cell aplasia is directly related to long term CAR T-cell persistence, which subsequently 
allows for both effector and central memory CAR expressing T-cells to partake in long 
term immunosurveillance (Porter et al., 2015).  
Nearly every patient who failed to respond to the CAR T-cell infusion progressed 
or died within a year following the infusion. This result further establishes the very 
advanced nature of CLL in patients enrolled in these studies. In CLL patients who 
initially achieved partial remissions (PRs), the cancer ultimately progressed for one of 
three reasons: 1) A preexisting condition, unrelated to the patient’s CLL, resulting in 
either necessary treatment that interfered with the CAR T-cell population persistence, or 
the patient’s death. 2) The patient’s CLL transformed into another cancer type (histologic 
transformation) that was unresponsive to the CAR T-cell therapy. 3) The CAR T-cells 
failed to persist in-vivo. None of the patients who achieved CR following the engineered 
T-cell infusion relapsed. The only death of a patient who achieved CR with CAR T-cell 
therapy is attributed to a complication following surgery for basal cell carcinoma, 
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unrelated to the patient’s CLL (Brentjens et al., 2011; Kochenderfer et al., 2012, 2013; 
Porter et al., 2015). 
The use of the CD28 costimulatory domain in CAR T-cell design in Kochenderfer 
et al.’s study, published in 2012, is particularly significant, as CAR T-cell infusions were 
followed by the administration of IL-2 until the patient’s cytokine mediated toxicities 
necessitated its cessation (Kochenderfer et al., 2012).  Preclinical studies have shown that 
CD28 costimulation elevates IL-2 levels, and that high IL-2 can impede the effector 
activity of CAR T-cells (D. W. Lee et al., 2014; Milone et al., 2009). Additionally, 
patients treated with IL-2 alone have been shown to experience cytokine toxicities 
(Panelli et al., 2004). Although the course of cytokine elevations in patients treated with 
both CAR T-cells and IL-2 differs from temporally from the typical course of IL-2 
related cytokine storm, it is possible that the combined effects of CD28 costimulation and 
exogenous IL-2 administration exaggerated cytokine elevations in these patients 
(Kochenderfer et al., 2012; D. W. Lee et al., 2014). It is therefore possible that 
withholding IL-2 treatment might have enhanced the outcomes of this trial.  
The results of most phase I clinical trials investigating CAR T-cell therapy in 
CLL patients reveal that disease progression relates temporally with the loss of the 
detectible engineered T-cell populations in the patient. Disease progression also 
coincided with lymphadenopathy reduction (Brentjens et al., 2011; Kalos et al., 2011; 
Kochenderfer et al., 2012). Although complete remissions were only induced in 6 of the 
30 enrolled patients, the ability to induce lasting, complete remissions in patients who do 
not require further therapy is a significant stride in treating this “incurable” cancer. More 
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significant still, is the ability to induce remissions in patients who relapsed after receiving 
allo-HSCTs, as these transplants were considered the only curative treatment option for 
CLL. Research has, thus far, proven that CAR T-cell therapy is capable of ablating large 
tumors in patients with rapidly progressing, advanced, CLL.   
Dr. Porter’s research group at the University of Pennsylvania is currently 
conducting a phase II dose-optimization trial to further study the clinical efficacy of CAR 
T-cell therapy in the treatment of CLL (Porter et al., 2013). 
 
Non-Hodgkin’s Lymphomas  
The great majority of published results from phase I clinical trials investigating 
the therapeutic efficacy of second generation CAR T-cell therapy in non-Hodgkin’s 
Lymphoma (NHL) has come from Kochenderfer’s research group at the National Cancer 
Institute (table 5).  These trials utilized CD28-coupled anti-CD19 CAR T-cells, and 
comprised a study population of patients diagnosed with Mantle Cell Lymphoma (MCL), 
Follicular Cell Lymphoma (FCL), Splenic Marginal Zone Lymphoma (SMZL), and 
Diffuse Large B-cell Lymphoma (DLBCL). Most patients in these trials experienced 
some degree of CRS. With the exception of notable neurologic toxicities, all adverse 
events resolved within three weeks after the CAR T-cell infusion (Kochenderfer et al., 
2012, 2013, 2015).  
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Table 5: Summary of Phase I Clinical Trials for Second Generation, Anti-CD19 
CAR T-cell Therapy in Patients Diagnosed with NHL 
Lymphoma 
Type 
Number of 
patients  
Number of 
patients who 
achieved 
complete 
remission  
Number 
of patients 
who 
achieved 
partial 
remission 
Longest 
recorded 
period of 
complete 
remission 
(months) 
Longest 
recorded 
period of 
partial 
remission 
(months) 
Longest 
recorded 
period of 
stable 
disease 
(months)  
SMZL 1 0 1 0 23+ 0 
PMBCL 4 2 0 N/R 22+ 1 
DLBCL (not 
otherwise 
specified) 
7 2 2 9+ 1 11+ 
Follicular 
Cell 
Lymphoma 
3 0 2 0 18+ 0 
Mantle Cell 
Lymphoma 
4 0 1 0 3+ 3+ 
N/R = not reported  
 
MCL is non-Hodgkin’s B-cell cancer that primarily affects elderly patients, and 
occurs more often in men than in women. The highly aggressive nature of this cancer 
renders it very difficult, in many cases impossible, to cure. While patients with low-risk 
MCL tend to respond well to therapy, most patients present with advanced MCL at their 
initial diagnosis (Geisler et al., 2010). A widely accepted, standard of care 
chemoimmunotherapy protocol to treat MCL has not yet been established (Bernstein et 
al., 2013; Delarue et al., 2013; Geisler et al., 2008; Romaguera et al., 2005). Younger 
patients diagnosed with MCL typically receive intensive chemoimmunotherapy followed 
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by autologous HSCT, while older patients may be treated less intensive, single agent or 
combination chemotherapy, or chemoimmunotherapy (Kluin-Nelemans et al., 2012; Y. 
Liu, Zhang, & Zhong, 2015; Ruan et al., 2015). Despite varied success of salvage 
chemoimmunotherapy, recently developed kinase inhibitors, and immunomodulatory 
agents, autologous HSCT is hailed as the only potentially curative therapy for high-risk 
MCL  (Y. Liu et al., 2015; M. Wang et al., 2012). 
The incidence of FCL, a relatively common, slow-growing (indolent) NHL, is 
positively correlated with advancing age. Patients often do not present with apparent 
symptoms at the time of their initial diagnosis (Solal-Céligny et al., 2004). In certain 
cases, FCL may undergo a histologic transformation in which this indolent cancer 
becomes a very aggressive lymphoma, such as diffuse large B-cell lymphoma (Giné et 
al., 2006). 
The indolent nature of FCL renders the “watch and wait” approach to treatment 
ideal for patients with early stage cancer. In this case, therapy will not be initiated until 
the cancer progresses. Patients who undergo treatment often receive radiation or 
induction chemoimmunotherapy, and maintenance therapy with a combination of 
rituximab and cancer-targeting radioactive particles  (Krause, Debus, & Neuhof, 2011). 
Aggressive salvage therapy regimens followed by autologous stem cell transplants are 
becoming more common methods of treating relapsed FCL. In patients for whom 
autologous stem cell transplantation has failed, allo-HSCT may be approached as the next 
therapeutic option. Further therapeutic options for FCL patients who relapse following 
allo-HSCT do not yet exist (Tarella et al., 2015). 
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Splenic marginal zone lymphoma is a rare, low-grade lymphoma that typically 
affects the elderly, accounts for less than 1% of non-Hodgkin lymphomas (Zucca, 
Bertoni, Roggero, & Cavalli, 1998). SMZL arises in the spleen and invades the bone 
marrow, peripheral blood, lymph nodes, and less commonly, the liver, as it progresses 
(Franco, Florena, & Iannitto, 2003). Due to its rare occurrence and indolent nature, few 
prospective trials have been conducted to investigate successful treatments for this 
neoplasm. As such, a definitive standard of care for SMZL has yet to be established. 
However, in nearly one third of the SMZL diagnosed patients, the cancer progresses so 
slowly that treatment is never required (Franco et al., 2003). The “wait and watch” 
approach is often employed in the treatment of these patients; therapy is not administered 
until the patients exhibit concerning symptoms of disease. In cases where SMZL is 
caused by hepatitis C infection, treating the patient for hepatitis C can effectively cure the 
patient of SMZL (F. Berger et al., 2000; Catovsky & Matutes, 1999a; Dreyling et al., 
2013)..  
Four treatment modalities are commonly employed in cases where SMZL directed 
treatment is necessary. Splenectomy, the most effective treatment for slowly progressing, 
early stage SMZL, is the first of four possible methods of treatment (Catovsky & 
Matutes, 1999b). Disadvantages to this approach include, long-term immunosuppression 
resulting from the loss of the spleen, and the consequent increased risk of infection 
(Lenglet et al., 2014; Xing et al., 2015). Single agent rituximab therapy, the second 
standard treatment method, has replaced chemotherapy as the preferred treatment in 
patients with non-metastasized SMZL who are ineligible for splenectomy (Dreyling et 
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al., 2013; Tarella et al., 2015). Chemoimmunotherapy, the third modality of treatment, is 
the preferred course for patients with advanced stage and/or aggressive SMZL at the time 
of diagnosis (Bennett, Yegena, Dave, & Schechter, 2008). Although there are several 
documented cases of patients achieving complete remissions, an optimal, curative 
combination of chemotherapeutic agents for aggressive induction therapy has not yet 
been established (Franco et al., 2003). Pancytopenia, among other conditions, can render 
a patient ineligible to receive chemotherapy. The fourth treatment modality, irradiation, is 
the preferred method for treating newly diagnosed SMZL patients who are ineligible to 
receive chemotherapy.  Although the benefits of splenic irradiation have been reported in 
only a small population of patients, studies show that low-dose radiotherapy can diminish 
the presence of various signs and symptoms of the cancer (El Weshi et al., 1998). 
Chemoimmunotherapy regimens are often administered as salvage therapy for relapsed 
and/or refractory SMZL patients.   
Kochenderfer et al.’s investigation, published in 2012, studied the effects of CD28 
coupled CAR T-cells in four CLL patients, as well as in three FCL patients, and one 
SMZL patient. The concerns of possible IL-2 mediated unfavorable outcomes, noted in 
the analysis of CLL patients enrolled in this trial, apply to NHL patients as well. 
Although investigators in this study assert that patients with severe CRS did not present 
with infections that could be concretely linked to sepsis via elevated cytokine levels, it 
must be noted that one FCL patient died of viral infection, bacterial infection, and 
cerebral infarction, among other conditions. In light of this patient’s late-stage, 
progressing cancer, it is possible that the patient’s death is unrelated to the CAR T-cell 
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infusion. Later investigations studying the extremely varied clinical presentation and 
physiological effects of CRS indicate that it is possible that CRS, or other adverse events 
that are commonly observed after CAR T-cell infusion, may have contributed to the 
patient’s death soon after the engineered T-cell infusion (Fitzgerald et al., 2016). 
Ultimately, this study produced PRs in two of the three FCL patients, revealing 
that it is possible to achieve a PR lasting greater than eighteen months with CAR T-cell 
therapy in this patient population. Additionally, the longest duration of B-cell depletion in 
this group was found to last 36 weeks. The significance of the period of B-cell deletion, 
and its relevance to engineered T-cell persistence, was not determined in this study. 
Notably, one FCL patient who achieved PR with a first round of CAR T-cell therapy 
relapsed within six months of a second CAR T-cell infusion for unknown reasons. As 
such, the relationship between this relapse and the persistence of CAR T-cells, B-cell 
aplasia, or the possibility of an escape variant, was not established in this study. The 
SMZL patient’s progress was reported in a later publication by this same group 
(Kochenderfer et al., 2012).  
The most commonly occurring NHL, DLBCL is consequently the most 
extensively studied type of lymphoma with regards to CAR T-cell therapy. DLBCL is a 
highly aggressive cancer characterized by proliferating neoplastic masses in the lymph 
nodes, bone marrow, spleen, and less commonly, other organs (Schneider, Pasqualucci, 
& Dalla-Favera, 2011).  Subtypes of DLBCL are named according to their location of 
origin, and the treatment for DLBCL varies according to the designated subtype. Primary 
Mediastinal B-Cell Lymohoma (PMBCL), for example, is a DLBCL originating in 
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thymic B-cells. The treatment for PMBCL differs slightly from treatments for other 
diffuse large B-cell lymphomas (DLBCLs). Though a standard treatment protocol for 
PMBCL has not been established, chemoimmunotherapy and radiation are commonly 
administered (Dunleavy & Wilson, 2015). 
 While some elderly patients diagnosed with DLBCL may undergo radiation 
therapy for bulky disease (Held et al., 2014), multi-agent chemoimmunotherapy have 
become the norm in the treatment of DLBCL. Although the four-year survival rate for 
patients initially diagnosed with DLBCL is around 65%, approximately one-third of 
patients diagnosed with DLBCL will develop relapsed or refractory disease. While the 
prognosis for patients with relapsed disease is poor, the prognosis for patients with 
chemotherapy refractory and/or rituximab refractory DLBCL is poorer still. If eligible, 
patients with relapsed and/or refractory disease may receive autologous HSCT following 
salvage therapy. Although patients with drug-refractory DLBCL are less likely to achieve 
CR with salvage therapy, studies have shown that autologous HSCT in this patient group 
are comparable to the results of this treatment modality in chemotherapy-sensitive 
relapsed patients (Guglielmi et al., 1998; Kewalramani et al., 2000).  Patients with 
chemoimmunotherapy-sensitive cancer who have relapsed within one year after induction 
therapy (early relapse) have lower overall survival rates and progression free survival 
rates compared to late relapsing patients (Hamadani et al., 2014; Mounier et al., 2012). 
An effective, curative therapy for early relapsed DLBCL and refractory DLBCL has yet 
to be established.  
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A 2013-published study investigated the success of CAR T-cell therapy in two 
DLBCL patients and 4 MCL patients, all of whom have disease that has relapsed after 
receiving allo-HSCT (Kochenderfer et al., 2013). In contrast to Kochenderfer et al.’s 
study published in 2011, patients in this clinical trial did not receive lymphodepleting 
chemotherapy prior to CAR T-cell infusions, or IL-2 treatment following the infusion, 
and donor lymphocytes, rather than autologous lymphocytes, served as the T-cell 
substrate (Kochenderfer et al., 2013).  
Notably, zero NHL patients in this study experienced high-grade adverse events 
or GVHD following the infusion. Only one MCL patient who was diagnosed with stable 
disease before enrollment achieved partial remission with CAR T-cell therapy. One MCL 
patient with partial regression at the time of enrollment was found to have stable disease 
persisting longer than three months after CAR T-cell infusion, and the malignancy status 
of the remaining four patients did not change with this therapy (Kochenderfer et al., 
2013). The results of this study reveal that a single course of second generation CD28 
coupled anti-CD19 CAR T-cell therapy is not a cure for MCL. It is possible, however, 
that the repeated administration of CAR T-cell infusions may improve the malignancy 
status of patients with MCL.  
The progress of the SMZL patient from Kochenderfer et al.’s 2012 publication 
was reported again in 2015. Kochenderfer’s group studied a single SMZL patient, who 
received three therapies prior to CAR T-cell infusion (Kochenderfer et al., 2015). The 
ability of CAR T-cell therapy to induce a partial remission lasting longer than 23 months 
is therefore a significant advancement in the treatment of high-risk SMZL.  
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Although Kochenderfer et al.’s 2015 study population was comprised of NHL and 
CLL patients with varying risks levels of malignancy, each patient received between two 
and twelve prior therapies for their cancer. All but two patients in this study had 
chemotherapy refractory disease. The patients without chemotherapy refractory disease 
were diagnosed with relapsed disease after receiving autologous HSCT (Kochenderfer et 
al., 2015).  
Two PMBCL patients and one DLBCL patient in this study exhibited notable 
adverse events that have not been previously reported in CAR T-cell therapy clinical 
trials for NHL patients. Neurologic toxicities unique to this study include aphasia, 
unilateral facial paresis, confusion and severe myoclonus that resolved within two weeks 
after the T-cell infusion, a mild tremor that resolved within one month post-infusion, and 
facial spasms and apraxia that resolved within 20 days post CAR T-cell infusion. Though 
the cause for these adverse events remains unknown, the low and intermediate 
malignancy-risk PMBCL patients were able to achieve CR and PR, respectively, while 
the high risk DLBCL patient achieved a status of SD after the CAR T-cell infusion 
(Kochenderfer et al., 2015).  
Kochenderfer’s 2015-published study reported the results of anti-CD19 CAR T-
cell infusions in a total of eleven DLBCL patients. Four of these patients were diagnosed 
with PMBCL, and one DLBCL patient acquired this lymphoma as the result of a Richter 
histological transformation of CLL. Autologous stem cell transplantation has long been 
considered the only curative therapy for high-risk DLBCL (Kewalramani et al., 2000). 
The successful results of this study are, therefore, remarkable. A PMBCL patient who 
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was diagnosed with stable disease after 6 cycles of chemoimmunotherapy, followed by 
radiation therapy, and an additional two cycles of chemoimmunotherapy, achieved a 
complete remission, lasting greater than 22 months following CAR T-cell therapy. In 
another example, a patient with high-risk chemotherapy-refractory DLBCL who received 
five prior therapies was able to achieve a CR lasting longer than 9 months.  All but one 
patient, a high-risk PMBCL patient with SD lasting one month, achieved either PR or CR 
with CAR T-cell therapy in this trial (Kochenderfer et al., 2015). The results of this study 
indicate that CAR T-cell therapy may be curative for high-risk DLBCL.  
Table 6. Results of Schuster et al.’s Phase IIa Clinical Trial 
Lymphoma 
Type 
3-month overall 
response rate 
Progression free survival rage at 
11.7 months (median follow up) 
Response duration at 11.7 
months (median follow up) 
DLBCL 54% 43% 83% 
MCL 50% N/R N/R 
FCL 100% 100% 100% 
Not Reported (N/R). 
The results of a Phase IIa clinical trial conducted at the University of 
Pennsylvania on a population of twenty-one DLBCL patients, fourteen FCL patients, and 
three MCL patients treated with CD137 coupled anti-CD19 CAR T-cells are presented in 
table 6. The study population consisted of patients with high-risk relapsed or refractory 
lymphoma for which no curative treatments were available. Only one patient in this study 
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developed severe CRS, and one patient experienced a severe neurologic toxicity 
(encephalitis). Although the extent of the malignancy for each patient following the 
therapy was not reported, treatment of high-risk FCL patients with anti-CD19 T-cells has 
shown the greatest promise in this trial (Schuster et al., 2015). 
Ongoing multi-center phase I clinical trials, as well as phase IIa clinical trials are 
being conducted to further evaluate the potential curative effects of CD19 CAR T-cell 
therapy in NHL patients (Locke et al., 2015).  
 
Multiple Myeloma 
Multiple myeloma is a cancer of plasma cells that presents with greatest incidence 
in elderly patients of African descent. Multiple myelomas account for approximately 15-
20% of all diagnosed hematologic malignancies, making it the second most commonly 
occurring hematologic neoplasm (Becker et al., 2007). The malignancy originates when 
genetic material is aberrantly altered during the maturation and differentiation of stem 
cells along the B-cell lineage within the bone marrow. Consequently, as the malignant 
plasma cell population expands, it invades the bone marrow and the bone, causing masses 
of plasma cells (plasmacytomas) that develop on bones. Patients with plasmacytomas are 
commonly treated with radiation (Krause et al., 2011). 
In the course of multiple myeloma progression, the expanding malignant plasma 
cell population produces large amounts of the abnormal immunoglobulin known as 
myeloma protein (M Protein). The abundance of M protein in blood can lead to kidney 
damage, dangerously viscous blood, and dampened immune responses. Due to the slow 
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growing nature of multiple myeloma, as well as the concerning toxicities, patients may 
not receive treatment until harmful levels of M protein are observed (Kusenda & 
Kovarikova, 2016).  
Novel chemoimmunotherapeutic agents, as well as the routine administration of 
allo-HSCT, when applicable, have shown great success in prolonging the survival of 
relapsed and refractory myeloma patients, achieving a 17-month median survival from 
the first diagnosis of relapsed disease (Rosenzweig & Krishnan, 2016). The mechanism 
behind the neoplasm’s repeated recurrence, in spite of these therapies, is the persistent 
presence of minimal residual disease over long periods of time, following treatment with 
standard therapies (Hsu et al., 1997).  
A published case study of a single patient with persistent disease following 
autologous stem cell transplantation revealed that second generation CD137 coupled anti-
CD19 CAR T-cells may be beneficial in the treatment of multiple myeloma. 
Interestingly, multiple myeloma is considered a CD19- cancer. While only 0.05% of the 
patient’s malignant plasma cells expressed CD19, this level of expression was enough to 
obtain a significant response to the CAR T-cell infusion. In this study, the patient 
received myeloablating chemotherapy, followed by autologous stem cell transplantation, 
and finally a CAR T-cell infusion. The successful expansion of the engineered T-cell 
population in-vivo did not cause CRS in this patient, although cytokine level rises were 
observed. B-cell aplasia was observed earlier than it would normally occur with 
chemotherapeutic agents alone, indicating successful on-target effects of the CAR T-
cells. The patient regained normal hematopoietic function, and non-malignant B-cell 
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development following the decline of the CAR T-cell population, indicating that the 
prolonged persistence past 47 days of CAR T-cells in-vivo is not required for the curative 
success of this therapy  (Garfall, Maus, Hwang, et al., 2015).  
Further investigations conducted by Garfall et al. following the same protocol of 
chemotherapy, autologous stem cell reinfusion, and CAR T-cell infusion achieved 
complete remissions in two of three evaluable multiple myeloma patients (Garfall, Maus, 
Lacey, et al., 2015). The results of these studies indicate that CAR T-cell therapy, in 
conjunction with autologous stem cell transplantation, can be curative for multiple 
myeloma patients.  
 
 
THIRD AND FOURTH GENERATION CAR T-CELLS 
The addition of a second and/or third costimulatory molecule(s) to the CAR 
structure has successfully enhanced CAR T-cell activation in preclinical models (Pulè et 
al., 2005b; J. Wang et al., 2007). The initial results of a phase I/IIa clinical trial using 
third generation anti-CD19 CAR T-cells coupled to both CD28 and 4-1BB costimulatory 
molecules in eleven patients with relapsed and/or refractory B-cell neoplasms, for whom 
no other curative options were available, are less promising. Six patients in this study 
were pre-treated with mild chemotherapy. The study revealed that the combination of two 
costimulatory molecules enhanced T-cell activation. However, the six patients relapsed 
within three months of receiving the infusion. The causes for these relapses are currently 
being investigated in this ongoing clinical trial (Enblad et al., 2016). While Enblad et al.’s 
results do not indicate any additional clinical benefits when compared to second 
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generation anti-CD19 CAR T-cells, third generation anti-CD20 cells have shown 
improved cytotoxic effects and in-vivo persistence when compared to their second 
generation counterparts (Till et al., 2012). Third and fourth generation CAR T-cell 
designs continue to be investigated in both in-vitro models, as well as in clinical trials.  
 
 
ALTERNATIVE CAR TARGETS 
The decreased B-cell expression of CD19 in many lymphomas, as well as relapses 
of CD19- ALL following CAR T-cell infusions, necessitates the study of other CAR 
targets. Research suggests that designing CAR T-cells against targets other than CD19 
may also improve the safety of CAR T-cells. CAR T-cell targets currently under 
investigation include cell surface markers, immunoglobulin light chains, and other tumor 
associated proteins (table 7).  
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Table 7. Potential CAR T-cell Therapy Target Alternatives Currently Under 
Investigation   
Alternative 
CAR T-cell 
Therapy 
Targets 
Suggested for 
Patients Diagnosed 
With... 
Reasoning Status of Current 
Investigations 
CD20 • B-NHL 
• B-ALL 
• Rituximab has been a successful 
therapy against B-cell malignancies 
(Vitolo et al., 2012). 
• Rituximab does not cause 
hypogammaglobulinemia (DiLillo et 
al., 2008). 
• CD20 expressed on most B-NHL 
and B-ALL cells (Davis, Czerwinski, 
& Levy, 1999; Thomas et al., 2009). 
Phase I Clinical 
Trials (Till et al., 
2012) 
CD30 • NHL 
• Hodgkin’s 
Lymphoma 
• B-cell Leukemia 
• T-cell Leukemia 
• Expressed on NHLs, Reed Sternberg 
Cells, B and T-cell leukemias (Di 
Stasi et al., 2009; A. Hombach et al., 
1998, 2001). 
Phase I Clinical 
Trials (C.-M. 
Wang et al., 2015) 
Ig Light Chains • B-cell 
Neoplasms  
• Malignant B-cells express an 
abnormal IgK/ Igλ ratio; this 
property can be exploited to target 
cancerous B-cells (Bergón, 
Miravalles, Bergón, Miranda, & 
Bergón, 2005). 
• Targeting Ig Light chains would not 
induce B-cell aplasia, or 
hypogammaglobulinemia, thereby 
protecting the patient’s infection-
fighting abilities (Vera et al., 2006). 
Preclinical Studies 
with Xenograft 
models 
BCMA • Multiple 
Myeloma 
• Plasma cells lack significant CD19, 
CD20, CD22, and Ig light chain 
expression (Craig & Foon, 2008). 
• B-cell maturation antigen (BCMA) is 
almost exclusively expressed on 
plasma cells. 
• Can eliminate plasma cells without 
inducing B-cell aplasia (Novak et al., 
2004). 
Phase I Clinical 
Trials (Carpenter 
et al., 2013; 
Fesnak et al., 
2016)  
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CD138 • Multiple 
myeloma 
• CD138 is expressed on plasma cells 
(Kawano et al., 2012). 
• Malignancy regressed in four out of 
five evaluable patients in an ongoing 
clinical trial with second generation 
4-1BB coupled anti-CD138 CAR T-
cells. 
Phase I clinical 
Trials (Guo et al., 
2016). 
ROR1 • NHL 
• B-ALL 
• Abnormally expressed receptor 
tyrosine kinase-like orphan receptor 
(ROR1) is a characteristic of many 
CLLs, mantle cell lymphomas, B-
ALLs (Hudecek et al., 2010). 
Phase I Clinical 
Trials (Deniger et 
al., 2015). 
CD22 • DLBCL 
• FCL 
• NHL 
• B-ALL 
• Many NHLs and B-ALLs express 
CD22 (Polson et al., 2010). 
Phase I Clinical 
Trials (Fesnak et 
al., 2016; Haso et 
al., 2013). 
CD33 • AML • Monoclonal anti-CD33 antibodies 
have been investigated as a therapy 
for Acute Myeloid Leukemia, a 
cancer caused by acquired mutations 
in bone marrow stem cells (Estey, 
Estey, & Estey, 2012; Jurcic, 2012). 
Phase I Clinical 
Trials (O’Hear, 
Heiber, Schubert, 
Fey, & Geiger, 
2015; Q. Wang et 
al., 2015, p. 33) 
 
 
The revolutionary success of rituximab in the treatment of B-cell neoplasms 
inspired the anticipated success of anti-CD20 CAR T-cells. Rituximab has not been 
shown to cause CD20- neoplastic escape variants or severe hypogammaglobulinemia, 
suggesting that anti-CD20 CAR T-cells may prove to be safer and more effective 
alternatives anti-CD19 CAR T-cells (DiLillo et al., 2008). However, early clinical trials 
failed due to unstable CAR expression, inadequate in-vivo persistence, and a failure to 
mount a significant response against CD20+ B-cells in-vivo (Till et al., 2008). Second 
generation anti-CD20 CAR T-cells that succeeded in inducing partial remissions in 
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DLBCL patients caused notable on-target off-tumor damage at sites of the cancer’s 
metastasis (Y. Wang et al., 2014). Though clinical trials of third generation anti-CD20 
CAR T-cells failed to obtain high levels of stable CAR expression, the therapy induced a 
response in MCL and indolent NHL, and was well tolerated by most patients in the study 
(Till et al., 2012). It is possible that transferring CAR genes through methods other than 
retroviral or lentiviral transduction will induce more stable expression of engineered 
receptors on anti-CD20 CAR T-cells, thereby supporting the future success of this target.  
While CD30 is expressed on many NHLs, Hodgkin’s Lymphomas, and B and T-
cell leukemias, it is also expressed on healthy progenitor cells and hematopoietic stem 
cells (HPSCs), allowing for potentially harmful on-target off-tumor effects of anti-CD30 
CAR T-cell therapy. In in-vitro preclinical studies, anti-CD30 CAR T-cells significantly 
eliminated both non-Hodgkin’s and Hodgkin’s lymphoma cells. In-vivo preclinical 
studies revealed that the eradication of lymphoma cells with anti-CD30 CAR T-cells is 
not coupled to B-cell aplasia (Di Stasi et al., 2009; A. Hombach et al., 1998, 2001). 
HPSCs were found to only minimally express CD30 in these studies, and thus both 
normal lymphopoiesis and hematopoiesis was conserved following engineered T-cell 
induction (A. A. Hombach et al., 2016). Phase I clinical trials to study anti-CD30 CAR T-
cells in lymphoma patients are currently being conducted.  
Despite the great clinical successes of CD19 targeting CAR T-cells, the search for 
a target that will confer maximal on-tumor effects with minimal additional toxicity 
continues. B-cells express a light chain of either immunoglobulin-K (IgK), or 
immunoglobulin- λ (Ig λ). The ratio of IgK/Igλ-expressing B-cells is maintained within a 
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narrow range in healthy humans, and deviation from this ratio is indicative of malignant 
clonal expansion (Bergón, Miravalles, Bergón, Miranda, & Bergón, 2005). Light chains, 
therefore, present an attractive target for CAR T-cell therapy. Second generation anti-IgK 
CAR T-cells with a CD28 costimulatory domain have been shown to successfully 
eradicate human lymphocyte-derived B-cells (Vera et al., 2006). These promising results 
indicate that future clinical trials will likely investigate the curative potential of light-
chain-targeting CAR T-cells in patients with advanced B-cell malignancies. 
Abnormally expressed receptor tyrosine kinase-like orphan receptor (ROR1), a 
protein known to assist cancerous cells in evading natural immune responses, is 
expressed on many B-cell malignancies and solid tumors (Hudecek et al., 2010). Anti-
ROR1 CAR T-cells successfully eradicated chemotherapy-refractory B-CLL and MCL in 
non-human primate models, and is currently being studied for its safety and clinical 
efficacy in a phase I clinical trial (Deniger et al., 2015; Hudecek et al., 2010, p. 1).  
 
 
IMPROVING CAR T-CELL THERAPY FOR THE TREATMENT OF B-CELL 
MALIGNANCIES  
 
Improving the CAR T-cell Manufacturing 
Currently, most manufacturing protocols enrich for CD3+ T-cells to serve as 
substrates for engineered T-cell production (Kalos et al., 2011; Kochenderfer et al., 2010; 
Savoldo et al., 2011). Growing evidence suggests that selecting for specific subsets of T-
cells may improve the proliferative potential and persistence of CAR T-cells in-vivo.  
 62 
Advantages to studying memory T-cell populations include their ability to quickly 
expand in response to antigenic stimulation, and the existing tumor specificity of memory 
T-cells derived from cancer patients. In theory, providing the patient differentiated, 
effector CAR T-cells prepared to mount an immediate response against cancer cells 
would be the most effective way to quickly eradicate the malignancy. However, effector 
T-cells have inferior proliferative abilities in comparison to memory and naïve T-cell 
groups. Studies in primate and murine models revealed that effector cells derived from 
TCM populations resisted T-cell exhaustion and conferred immunologic memory in-vivo 
more successfully than TEM derived effector cells (C. Berger et al., 2008; Klebanoff et al., 
2005). In-vitro experiments and in-vivo studies in murine models revealed that effector 
cells derived from naïve T-cells are less differentiated, express fewer markers of T-cell 
exhaustion, and have longer telomeres, all of which confer greater proliferative success 
than memory T-cell substrates (Hinrichs et al., 2009, 2011). Recent clinical studies 
confirm that naïve TC cell-derived effector cells are superior substrates for CAR T-cell 
therapy in their cytotoxic potency and proliferative potential (Nguyen et al., 2016). 
Future advancements in CAR T-cell therapy will likely select for naïve TC cell-derived 
effector substrates.  
Common setbacks currently hindering the success of CAR T-cell therapy’s 
efficacy include varying rates of gene transfer, and unreliable CAR expression. While the 
transposon/transposase system of gene transfer is currently gaining popularity as a safer, 
more cost-effective alternative to retroviral transduction, messenger RNA (mRNA) 
transfer may prove to be a more successful method of gene transfer for CAR T-cell 
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therapy. In this method, mRNA is introduced into the cell by non-viral methods, most 
often via endocytosis, microinjection, or electroporation. Transcription can then be 
induced in-vitro. This method does not involve genomic integration, and results in stable, 
transient transgene expression. Messenger RNA transfer-mediated gene expression 
therefore circumvents potential genotoxicity problems associated with retroviral 
transduction (Rowley, Monie, Hung, & Wu, 2009). This process has successfully 
promoted protein expression in hematopoietic progenitor cells (Wiehe et al., 2007), and 
has been studied for TCR expression in TCR therapy as well (Zhao et al., 2006). It is 
currently being investigated in preclinical studies for CAR T-cells, as a method of 
examining the potential cross reactivity of CARs and healthy human tissues (Beatty et al., 
2014).  
 
Improving CAR T-cell Efficacy 
Many scientists have asserted that the success of CAR T-cell therapy is related to 
the patient’s tumor burden at the time of infusion (Davila & Brentjens, 2013; Gattinoni et 
al., 2005; Kochenderfer et al., 2012). The extremely varied responses of patients within 
study groups indicates that further advancements of CAR T-cell therapy rely on a 
concrete understanding of how various disease factors impact a patient’s response to 
therapy. Such an understanding can further support the success of CAR T-cell therapy in 
the arena of personalized medicine, by tailoring pre-treatments, dosages of CAR T-cells, 
and receptor targets to each patient’s malignancy and health status.  
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Administering two or more sets of CAR T-cells in an infusion, each recognizing a 
different target, may mitigate the relapse of cancer due to downregulated CD19 variants 
(Sotillo et al., 2015). Anti-CD123 CAR T-cells successfully eradicated CD19- B-ALL in 
murine models. Additional preclinical studies show that administering a dosage of CAR 
T-cells composed of both anti-CD19 CAR T-cell and anti-CD123 CAR T-cell 
populations eradicated relapsed B-ALL, improved overall survival, and did not result in 
escape variants (Ruella et al., 2015). Such results indicate that multivalent targeting with 
combinations of CAR T-cells designed against different targets may successfully prevent 
the relapse of target-down-regulated escape variants.  
Combining CAR T-cell therapy with other commonly administered therapies, 
such as the Bruton’s tyrosine kinase binding protein, ibrutinib, has been shown to 
increase the anti-tumor clinical efficacy of CAR T-cells in preclinical investigations 
(Ruella et al., 2016). Mononuclear antibodies, such as rituximab and blinatumomab, are 
commonly used in conjunction with chemotherapeutic agents to enhance the anti-tumor 
effects of both chemotherapy and immunotherapy agents (Bennett et al., 2008; 
Gisselbrecht et al., 2012). Combination therapy regimens to enhance the efficacy of CAR 
T-cells is therefore a logical next step for adoptive immunotherapy research.  
 
Improving the Safety of CAR T-cell Therapy 
Although second generation anti-CD19 CAR T-cell therapy is considered 
generally safe, and most severe adverse events have been either self-limiting or 
reversible, the recent fatalities of three B-ALL patients from cerebral edema in a phase II 
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clinical trial conducted by Juno Therapeutics reinforces the need for additional safety 
measures in CAR design. CAR T-cells have been shown to induce severe toxicities 
resulting from on-target on-tumor activity, such as CRS, tumor lysis syndrome, and 
encephalopathies, as well as insertional mutagenesis, and GVHD resulting from donor 
derived T-cell substrates, among other complications (Brentjens et al., 2011; Grupp et al., 
2013, 2013; Kalos et al., 2011; Kochenderfer et al., 2012; Porter et al., 2011; Savoldo et 
al., 2011). While it is possible that designing CARs against targets other than CD19 may 
improve the safety of the engineered cells in-vivo, adding a molecular “off-switch” to the 
design of CAR T-cells is currently a promising strategy to avoid the onset of potentially 
fatal adverse events.    
A number of switch-mediated CAR T-cell designs are gaining popularity as built-
in safety mechanisms for T-cell immunotherapy. Administering a chemical induction of 
dimerization product, known as AP1903, will initiate iCasp9 mediated cellular apoptosis 
upon command to destroy the CAR T-cells and prevent the progression of severe adverse 
events. Second generation anti-CD19 and third generation anti-CD20 CAR T-cells 
designed with an iCasp9 “safety-switch” showed enhanced anti-tumor effects in-vivo and 
fewer markers of T-cell exhaustion, with the ability to be safely eliminated once 
apoptosis was induced in murine models (Budde et al., 2013; Hoyos et al., 2010). The 
safety and efficacy of the iCasp9 system has been proven in allo-HSCTs. Scientists are 
actively planning phase I clinical trials to evaluate the success of this system for third 
generation CAR T-cell therapy against relapsed, indolent B-NHL (Budde et al., 2013; Di 
Stasi et al., 2011).  
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Designing CAR T-cells to express molecular makers present on a cancer, such as 
CD20, would allow for the elimination of CAR T-cells in cases of post-infusion toxicities 
with the administration of a commonly used monoclonal antibody, such as rituximab. 
Such a method of CAR T-cell elimination would have the added benefit of anti-tumor 
cytotoxicity (Philip et al., 2014). These constructs will likely be tested in clinical trials in 
the near future. However, the destruction of CAR T-cells with this design, as well as 
molecular “off-switch” designs, will inevitably eliminate the anti-tumor effects of this 
therapy.  
Preclinical models have shown CAR T-cells with molecular “on-switches” to be 
both safe and feasible alternatives to on-demand CAR T-cell destruction. This novel 
approach would require the administration of an activating molecule to stimulate T-cell 
activation in-vivo, and thus would allow physicians to tailor CAR T-cell activation to the 
patient’s individual condition and tolerance for the engineered T-cells (June, 2016; 
Rodgers et al., 2016). 
 
 
CONCLUSIONS AND FUTURE DIRECTIONS  
Many scientists assert that the ultimate end-goal of adoptive T-cell therapy is to 
shift this personalized medical therapy to the realm of commercially-produced, “off-the-
shelf,” cancer curing products. This goal entails designing CAR T-cells against a variety 
of targets, made with donor derived T-cell substrates, that can be administered with the 
ease and efficiency of current monoclonal antibody immunotherapies (Campbell et al., 
2015; Xiuyan Wang & Rivière, 2016). Notably, the ability of donor-derived CAR T-cells 
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to cause GVHD is a significant complication that can dismantle the potential success of 
commercially-produced CAR T-cells. Expediting the manufacturing process, decreasing 
the cost of production, and improving the reliability of the CAR T-cell products, in terms 
of their stable expression of CARs and safety in-vivo, are examples of critically 
important factors that must be considered before mass-produced CAR T-cells are a 
feasible reality.  
Alternatively, the increasing popularity of personalized medicine suggests that the 
greatest success of CAR T-cell therapy may come from maintaining the benefits of 
autologous T-cell substrates. Regardless, decreasing the cost and increasing the efficiency 
of CAR T-cell production will likely result in significant benefits to the availability and 
feasibility of CAR T-cell therapy as a treatment for B-cell malignancies. Although 
significant variations in design, gene transfer efficiency, and safety concerns have yet to 
be concretely addressed in human patients, preclinical studies have shown great success 
in mitigating these concerns.  
 Second-generation anti-CD19 CAR T-cell therapy has cured patients diagnosed 
with B-ALL, and induced lasting complete remissions and prolonged the survival of 
patients with advanced B-CLL and B-NHL. Although the success of this therapy varies 
per the patient’s malignancy and disease status, current research suggests that 
reproducible, beneficial results with other CAR T-cell targets can be expected in the near 
future. The remarkable results of phase I and II clinical trials in high-risk, relapsed and 
refractory cancer indicate that CAR T-cell therapy holds a promising future as a cure for 
hematologic B-cell malignancies. 
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